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Introduction 
Introduction 
 
Thyroid hormone action 
Thyroid hormones, that is, 3,5,3’-triiodothyronine (T3) and 3,5,3’,5’-tetraiodothyronine (T4), 
influence a variety of physiological processes, including cell growth, differentiation and 
metabolism in mammals, metamorphosis in amphibia and development of the vertebrate 
nervous system (Zhang and Lazar, 2000; Shi et al, 1998; Koibuchi and Chin, 2000). 
Thyroid hormones are essential for normal development, growth and metabolism (Yen, 
2001). The pro-hormone thyroxine (T4) is synthesized in the thyroid gland together with a 
small amount of the active hormone 3,5,3′- -triiodothyronine (T3). However, the majority of 
circulating T3 is generated by pre-receptor ligand metabolism resulting from activity of the 
iodothyronine deiodinase enzymes D1 and D2 which convert T4 to T3 by 5′ 
monodeiodination. In contrast, the D3 enzyme inactivates T4 and T3 by 5′ 
monodeiodination. Thus, the intracellular level of T3 is dependent on the relative activities 
of these three deiodinases (Bianco et al., 2002). 
The growth-stimulatory effect of T3 has long been recognized in various cellular systems in 
vitro:  in rat cerebellar astrocytes and glia cells (Trentin et al, 2001), in rat pituitary cells 
(Barrera-Hernandez et al, 1999), in hepatocyte proliferation in rats  (Francavilla et al, 1994; 
Pibiri et al, 2001), and in experiments on gene therapy and re-population of hepatocytes 
(Ledda-Columbano et al, 2000). Recent studies indicate that all these effects are mediated 
by the interaction of T3 with the thyroid hormone nuclear receptors (TRs) (Yen, 2001), 
ligand-dependent transcription factors and members of the steroid hormone/retinoic acid 
receptor superfamily (Ribeiro et al, 1998).  
The actions of thyroid hormone occur through its binding to the thyroid hormone receptor 
(TR). TR is a nuclear hormone receptor, which heterodimerizes with Retinoid X receptor, 
or in some cases, with itself. The dimers bind to the thyroid response elements (TREs) in 
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the absence of ligand and act as transcriptional repressors. The active form of thyroid 
hormone, 3,5,3’, triiodo-L-thyronine (T3), binds to TR with much greater affinity than the 
more abundant 3,5,3’,5’ tetraiodo-L-thyronine (T4). Binding of T3 to TR depresses TRE-
dependent genes and induces the expression of target genes. This way of action of TRs 
and of the other steroid receptors, as ligand-dependent transcription factors, has been 
traditionally involved in the genomic action of T3, which have a considerable latency with 
response times in hours to days 
 
Thyroid hormone nongenomic effects 
However, a number of steroid hormone mediated actions occur within a far more rapid 
time frame of only a few minutes and are thus incompatible with the classical genomic 
model of action ( Losel and Wehling, 2003). Such rapid non-genomic responses include 
the progesterone mediated acrosomal reaction ( Osman et al., 1989), vasoregulation by 
estrogens, mineralocorticoids and glucocorticoids ( Shaul, 1999; Hafezi-Moghadam et al., 
2002 and Losel et al., 2002), and calcium signalling, thermogenesis and the lipolytic 
activites of catecholamines by thyroid hormone ( Davis et al., 1989; Lynch et al., 1985; 
Segal, 1989 and Wrutniak and Cabello, 1986). Non-genomic or non-classical steroid 
hormone effects encompass any action that does not directly effect nuclear gene 
expression. Such non-genomic actions frequently have a short latency, are unaffected by 
inhibitors of transcription and translation, have agonist and antagonist affinity and kinetics 
divergent from the classical nuclear receptor and persist in genetically modified mice that 
lack the classical nuclear receptors. These non-genomic responses are frequently 
associated with secondary messenger signalling pathways including the phospholipase C 
(PLC), inositol triphosphate (IP3), diacyl glycerol (DAG), protein kinase C (PKC) and Ca2+I 
pathway, the adenylyl cyclase, protein kinase A (PKA) and the cyclic AMP-response 
element binding protein (CREB) pathway and the Ras, Raf1 serine/threonine kinase, 
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mitogen activated protein kinase kinase (MEK) and the mitogen activated protein kinase 
(MAPK) pathway (Losel and Wehling, 2003). It has been suggested that such non-
genomic actions might be mediated by either membrane associated isoforms of the 
classical nuclear receptors or by novel membrane receptors with significantly different 
agonist/antagonist affinities ( Losel and Wehling, 2003). The recent identification of such 
receptors for progestins and estrogens has highlighted the non-genomic actions of steroid 
hormone ( Li et al., 2003; Zhu et al., 2003 and Zhu et al., 2003).  
Estrogens are associated with rapid increases in intracellular calcium in endometrial cells 
(Pietras and Szego, 1975), induction of the phosphatidylinositol 3-kinase (PI3Kinase), 
Ser/Thr kinase Akt, endothelial NO synthase (eNOS) pathway in endothelium ( Haynes et 
al., 2000), with Giα activation ( Russell et al., 2000 and Wyckoff et al., 2001) and with 
ERK/MAPK signalling ( Watters et al., 1997). It has been uncertain whether these actions 
are mediated by the classical estrogen nuclear receptor (ER) localized in the cell 
membrane or by a novel membrane receptor ( Pietras and Szego, 1977 and Razandi et 
al., 2002). Even for thyroid hormones, in addition to the genomic  or TRE-mediated effects 
of T3, non-nuclear or TRE-independent actions of T3 have recently been described. 
Although T3 is known to exert many of its actions through the classical genomic regulation 
of gene transcription, a number of T3 effects occur rapidly and are unaffected by inhibitors 
of transcription and protein synthesis (Davis et al., 1989 and Davis et al., 2000; Wrutniak-
Cabello et al., 2001). However, the levels of circulating thyroid hormones are tightly 
regulated and stable and thus rapidly mediated responses must involve regulation of pre-
receptor ligand metabolism, ligand membrane transport or receptor availability leading to 
local cell type specific variation in thyroid hormone signalling. 
 Non-genomic actions of thyroid hormones have been described at the plasma membrane, 
in the cytoplasm and in cellular organelles (Henneman et al, 2001). 
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As steroid hormone action, thyroid hormone non genomic action has been related to 
various second messenger signaling pathways. They have included the modulation of Na+, 
K+, Ca2+ and glucose transport, activation of PKC, PKA and ERK/MAPK and regulation of 
phospholipid metabolism by activation of PLC and PLD (Kavok et al., 2001) In vitro, 
independent of protein synthesis, T4 induces IP3 and calcium signalling and augments the 
effects of IFNγ via PKC and PKA (Davis et al., 1989; Lakatos and Stern, 1991 and Lin et 
al., 1997). In addition, T4-linked to agarose, which does not cross the plasma membrane, 
has been shown to activate MAPK by a pertussis toxin sensitive mechanism suggesting 
the actions of a G protein-coupled thyroid hormone membrane receptor ( Lin et al., 1999). 
In vivo, T4 regulates thermogenesis and the lipolytic activites of catecholamines within 
30 min (Lynch et al., 1985 and Wrutniak and Cabello, 1989). Non-genomic effects of 
thyroid hormone have also been reported in the myocardium and vasculature. T3 
enhances cardiac output and reduced systemic vascular resistance in normal adult males 
within 3 min (Schmidt et al., 2002) and cell culture studies suggest that thyroid hormones 
rapidly, and non-genomically, regulate the Ca2+ATPase enzyme, the Na+ channel (INa) via 
PKC, the K+ channel (IK ) via PI3-kinase, the Na+/H+ anti-porter via PKC and MAPK and 
the inward rectifying potassium channel (IK1) (Davis and Davis, 2002). T3 also increases 
sarcoplasmic reticulum Ca2+, cell shortening, contractility and calcium mediated arrhythmic 
activity suggesting that T3 has a non-genomic, positive ionotropic and arrhythmagenic 
effect (Wang et al., 2003).  
In pituitary cells, T3 has been shown to non-genomically stimulate the ether-a-go-go 
related gene potassium channel (ERG/KCNH2), which reduces endocrine neuronal 
excitability, via PI3 kinase and the Rac GTPase, whereas TRH (thyroid releasing 
hormone) inhibits ERG activity via PKC and the Rho GTPase to increase neuronal 
excitability (Storey et al., 2002). These observations suggest a possible role for non-
genomic T3 signalling in the hypothalamic/pituitary feedback loop..  
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Although 10% of TRs are cytoplasmic in the absence of T3 (Baumann et al., 2001) no 
specific membrane associated TR isoform has been identified. Nevertheless, it has been 
postulated that T4 may interact with a novel G-protein coupled membrane receptor 
(GPCR) ( Lin et al., 1999) leading to rapid serine phosphorylation of nuclear TRs ( Davis et 
al., 2000). This proposed model of Davis and others for the cell surface mediated non-
genomic actions of thyroid hormone has been suggested to involve the MAPK and PI3-
kinase signalling cascades ( Lin et al., 1999 and Storey et al., 2002). This model suggests 
that, over a time period of 10–30 min, T4 binds a cell surface GPCR (Lin et al., 1999), 
activates PKC, Ras, Raf1 and MEK resulting in tyrosine phosphorylation, activation and 
nuclear translocation of MAPK, which in turn phosphorylates a serine residue in the 
second zinc finger of TR ( Davis et al., 2000 and Shih et al., 2001). This phosphorylation 
results in dissociation of TR from the co-repressors SMRT and NCoR, decreased protease 
degradation, increased the trascriptional activity ( Jones et al., 1994; Leitman et al., 1996 
and Ting et al., 1997) and may also regulate RXR heterodimerization ( Katz et al., 1995). 
The nuclear MAPK/TR complex has also been shown to bind and phosphorylate p53 to 
regulate its transcriptional activity ( Shih et al., 2001). In a parallel pathway, T4-activated 
MEK phosphorylates tyrosine residues in STAT1α and STAT3 (signal transducers and 
activators of transcription) resulting in their nuclear translocation, further serine 
phosphoylation by MAPK and activation of gene transcription ( Lin et al., 1999). The non 
genomic actions of thyroid hormone may therefore influence gene transcription by at least 
three distinct pathways STATs, p53 and TRs. T4 is also thought to initiate DAG formation 
by phospholipase C resulting in the subsequent PKC activation of phospholipase D ( 
Kavok et al., 2001).  
Activation of MAPK by thyroid hormone T3 and rapid modulation of specific cascades 
imply the existence of  membrane receptors for the hormone that may be linked to signal 
transduction pathways. Membrane binding sites for thyroid hormones were identified years 
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ago in cell membranes isolated from human and rat hepatocytes (Pliam and Goldfine, 
1997, Gharbi J and Torresani J, 1979). It has been recently demonstrated (Bergh et al. 
2005) that the extracellular domain of a structural membrane protein, integrin αVβ3, is 
capable of binding thyroid hormone T4 thus activating the MAPK pathway.  
These many observations suggest that the rapid non-genomic effects of thyroid hormone 
are widespread and may be involved in multiple physiological processes in many different 
cell types. However, no specific membrane associated TR isoform or thyroid hormone 
binding G protein-coupled receptors have been identified or cloned and thus the area 
remains controversial. 
 
 
Thyroid hormone action: from entrance into the cells to the nuclear and cytosolic action. 
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(from: Moeller et al, 2006) 
Genomic (1) and non-genomic (2) actions of TH are illustrated. Genomic action requires 
thyroid hormone responsive elements (TREs) for the recognition of genes for direct 
transcriptional regulation. Non-genomic action is initiated by the TH-dependent activation of 
PI3K as illustrated in Figure 2. Activation of PI3K leads to sequential activation of Akt/PKB-
mTOR-p70S6K. Although not well defined, this cascade leads to transcriptional upregulation of 
some genes such as ZAKI-4α and HIF-1α. GTF: general transcription factors.   
 
 
Thyroid hormone receptors 
Thyroid hormone receptors (TRs) play a major role in animal physiology. TRs are 
important and very interesting regulators of diverse aspects, including brain development, 
hearing, bone growth, morphogenesis, metabolism, intestine, and heart rate in vertebrates. 
Aberrant functions of TRs induce tremendous defects in these pathways. For example, the 
human disease of Resistance to Thyroid Hormone (RTH) is a genetically autosomal 
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dominant inherited syndrome that is caused by mutations in the gene encoding the TRβ. 
The role of the ligand of TRs, the thyroid hormone, is to modulate the activity and 
functionality of TRs. T3 receptors are members of a family of hormone-responsive nuclear 
transcription factors that are similar in structure and mechanism of action. The functional 
domains of the receptor include a carboxy-terminal portion, which is important for ligand 
binding and interactions between receptors, a DNA-binding domain, and an amino-terminal 
domain, which does not have an identified functional role . The domain that interacts with 
DNA includes two sequences of amino acids with cysteine residues that form loop 
structures and chelate a zinc atom, termed "zinc fingers". Several amino acids within this 
structure serve to determine the specific DNA sequence to which the monomeric receptor 
binds; others are important for receptor dimerization, the usual functional form for positive 
regulation. The nature of the DNA sequences that bind T3 receptors is central to determine 
which genes are stimulated or inhibited by T3. In vitro, T3 receptors bind to DNA as 
homodimers or as heterodimers with other nuclear proteins, such as the retinoid X receptor 
(whose ligand is 9-cis-retinoic acid). T3 disrupts the binding of T3-receptor homodimers to 
DNA, but not that of T3-receptor heterodimers. The ligand-binding domain confers 
specificity for T3, and mutations in this domain can result in tissue resistance to thyroid 
hormone.  
There are two TR two genes, THRA and THRB, located on human chromosomes 17 and 
3, respectively (Yen, 2001, Harvey and Williams, 2002 and Zhang and Lazar, 2000). The 
THRA gene generates two mature mRNAs by alternative splicing that encode two 
proteins, TRα-1 and c-erbAα-2, that differ in their carboxy-termini. TRα-1 is a bona fide 
receptor whereas c-erbAα-2 is unable to bind TH and blocks TR-mediated transcription. 
The THRB gene encodes two TR isoforms, TRβ-1 and TRβ-2, which most likely are 
generated by alternative promoter choice (Williams and Brent, 1995) and have differing 
amino-terminal regions. The major TR isoforms (TRα-1, β-1, β-2) bind T3 with high affinity 
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and mediate thyroid hormone-regulated transcription. They also have highly conserved 
DNA-binding and ligand-binding domains. 
Recent findings have elucidated the role of nuclear TRβ1 in mediating some T3 action on 
cell proliferation (Porlan et al. 2004) and in regulation of specific cell survival cascades 
(Cao et al. 2005),  therefore TRβ1 has been cited as a good candidate for mediating 
thyroid hormones (TH) nongenomic action. 
 
 
 
 
 
 
 
 
Thyroid hormone receptor and its ligand
 
 
 
β cell failure in diabetes 
Compelling evidences suggest that apoptosis is the principle mode of β-cell death during 
the development of type 1 and type 2 diabetes (Mauricio and Mandrup-Poulsen, 1998; 
Chandra et al, 2001). Type 1 diabetes (T1D) is an autoimmune disorder resulting from the 
destruction of insulin-producing β-cells of pancreatic islets principally by cytotoxic 
cytokines secreted by infiltrating leukocytes (Mathis et al, 2001). Type 2 diabetes (T2D) is 
associated with reduced insulin secretion and glucose toxicity that may contribute to β-cell 
death (Cerasi et al, 2000; Mandrup-Poulsen, 2001).  
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Type I insulin-dependent diabetes mellitus (IDDM) is an autoimmune disease that 
results from the destruction of insulin-secreting pancreatic islet beta-cells by autoreactive 
cells and their mediators, such as cytokines (Sjoholm, 1998; Kreuwel and Sherman, 2001). 
Several recent studies have investigated the role of cell apoptosis in the events leading to 
the immune-mediated loss of beta-cells either in vitro or ex vivo. Based on studies of 
pancreatic biopsies taken from diabetes-prone and diabetes-resistant BB/S rats, Lally et 
al. (2001) showed that the appearance of beta-cell apoptosis in the diabetes-prone group 
was detectable as early as 68 days of life (long before the onset of diabetes). This was 
followed by an acceleration of apoptosis rate around 85 days of age in the diabetes-prone 
group, which co-incided with the onset of hyperglycemia. Similarly, Augstein et al. (1998), 
using NOD (non-obese diabetic) mice, demonstrated that the frequency of apoptosis of 
islet cells correlated with the progression of beta-cell destruction and the decline of 
glycemic control. 
Type II diabetes mellitus is characterized by an asymptomatic insulin resistance 
phase preceding the onset of diabetes, while hyperglycemia occurs when a relative insulin 
secretory deficiency is manifest (Cerasi et al., 2000; Mandrup-Poulsen, 2001). Studies 
from autopsies of subjects affected by Type II diabetes demonstrated that in some, 
although not all individuals with diabetes, there is a marked decrease in beta-cells mass 
compared to control normoglycemic subjects (Yagihashi, 1996). While a smaller beta-cells 
mass could result from either an insufficient proliferative capacity or from an excessive rate 
of cell death, there is evidence of other attributable factors. Several studies have 
demonstrated that in vitro, free fatty acids, glucose, sulfonylurea, and the islet cell 
hormone termed amylin can cause beta-cell apoptosis. This suggests that programmed 
cell death may also be involved in the pathogenesis of Type II diabetes (Schwingshackl et 
al., 1998; Shimabukuro et al., 1998; Garratt et al., 1999; Federici et al., 2001). Cell 
apoptosis has also been shown to be the mechanism leading to beta-cells loss in the 
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Zucker diabetic fatty (ZDF) rat, another model of Type II diabetes. In ZDF rats, the rate of 
beta-cell proliferation or neogenesis is not reduced and hyperglycemia is detected when 
the expansion of beta-cells mass is no longer capable of compensating for the degree of 
insulin resistance and beta-cells apoptosis (Pick et al., 1998; Farilla et al., 2002). 
  
The Akt pathway and its crucial role in β cell function 
It has recently become evident that PKB/Akt activation plays a pivotal role in β-cell survival 
(Lingor et al, 2003). In fact, the expression of a constitutively active variant of Akt in β-cells 
prevents free fatty acid-induced apoptosis (Wrede et al, 2002) and the transgenic β-cell 
specific expression of the same active Akt is protective against streptozocin-induced 
diabetes in mice (Tuttle et al, 2001). In pancreatic β-cells, PKB/Akt can be activated by 
different factors, as IGF-1 and GLP-1 (Buteau et al, 2001; Giannoukakis et al, 2000). 
When activated, via a cAMP-dependent or independent mechanism, Akt plays a central 
role in mediating a number of cellular processes, including mitogenesis, survival and 
differentiation.  Most of the downstream proteins of Akt activity are likely expressed in β-
cells and might be considered as molecular targets in preventing β-cell death.  
Thyroid hormone T3 is also involved in the PI3K pathway: it has recently been reported to 
regulate the Na,K-ATPase activity via PI3K in alveolar epithelial cells (Lei et al. 2004) and 
to activate the protein kinase B via PI3K, in human fibroblasts (Cao et al. 2005). Estrogen 
and retinoic acid have also been recognized to activate PI3K rapidly through the 
nontranscriptional action of their receptors (Simoncini et al. 2000; Sun et al. 2001; Haynes 
et al. 2003; Lopez-Carballo et al. 2002). Furthermore, estrogen receptor-α was 
demonstrated to activate PI3K through binding with p85α either in a ligand-dependent 
manner in endothelial cells (Simoncini et al. 2000) or in a ligand-independent manner in 
epithelial cells (Sun et al. 2001). 
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Cellular processes such as proliferation, survival and glucose metabolism induced by 
different hormones and growth factors are dependent on the activation of PI-3 Kinase 
generating D3-phosphorylated phosphoinositides that are capable of binding PKB/Akt . 
(Ueki K et al. 2002; Liang et Slingerland, 2003). Akt has been implicated as a critical 
mediator of insulin-stimulated glucose uptake, suppression of apoptosis, stimulation of 
glycolysis and activation of glycogen and protein synthesys in various cell-culture systems 
(Coffer PJ et al. 1998). It has recently become evident that PKB/Akt activation plays a 
pivotal role in β-cell survival (Lingor et al. 2003) and growth.; moreover recent evidences 
reviewed in Elghazi et al. (2006) underscores the importance of Akt for regulation of β cell 
mass and function.  In pancreatic β-cells,  PKB/Akt can be activated by different factors, 
such as IGF-1 and GLP-1 (Buteau et al. 2001; Giannoukakis et al. 2000), and it is directly 
activated by glucose (Dickson and Rhodes, 2004). When activated, via a cAMP-dependent 
or independent mechanism, Akt mediates a large number of cellular processes, including 
mitogenesis, survival and differentiation. 
Activation of Akt/PKB results in phosphorylation of many substrates that control various 
biological signaling cascades including insulin-mediated glucose transport, protein and 
glycogen synthesis, proliferation, cell growth, differentiation, and survival (Ahlgren et al., 
1996 and Woodgett, 2005). The loss of Akt1/PKBα resulted in normal carbohydrate 
metabolism and both fetal and postnatal growth defect (Chen et al., 2001 and Cho et al., 
2001b). In contrast, Akt2/PKBβ-deficient mice exhibited impaired glucose disposal and 
diabetes due to a reduction in insulin-stimulated glucose uptake in peripheral tissues and 
β-cell failure (Cho et al., 2001a). These results suggest that Akt/PKB could play a role in β-
cell adaptation to insulin resistance states. Akt1/Akt2 double-knockout mice showed 
severe growth deficiency, impaired skin development, and skeletal muscle atrophy, and 
died shortly after birth. The generalized defect in conventional knockouts and expression 
of different Akt/PKB isoforms with similar biochemical characteristics makes the alterations 
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in β-cell function in these animal models difficult to interpret. Moreover, overexpression of 
constitutively active Akt/PKB in β-cells in transgenic mice resulted in augmented β-cell 
mass by increase in proliferation and cell size and these mice were resistant to 
streptozotocin-induced diabetes (Bernal-Mizrachi, Wen, Stahlhut, Welling, & Permutt, 
2001; Tuttle et al., 2001). Transgenic mice with reduction of Akt/PKB activity in β-cells 
exhibited normal β-cell mass and defective insulin secretion (Bernal-Mizrachi et al., 2004). 
Based on these results and experiments in cell lines, it is likely that Akt/PKB is a major 
mediator of the responses to insulin, insulin-like growth factor (IGFI), incretins, and 
glucose. The molecules and the mechanisms involved in the regulation of β-cell mass and 
function by Akt/PKB in β-cells are ill defined, but a specific role for this kinase in regulating 
pancreatic beta cell proliferation, neogenesis, apoptosis and size together with insulin 
secretion can be discussed.   
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In vivo and in vitro experiments suggest that Akt/PKB could mediate the proliferative 
signals induced by activation of Irs2 signaling (Kitamura et al., 2002 and White, 2002). 
While the regulation of cell cycle by Akt/PKB has been studied in other model systems, 
there is little information about its role in cell cycle progression in β-cells (Chang et al., 
2003). Recent experiments show that activation of Cdk4 is indispensable for β-cell 
proliferation induced by Akt/PKB (Bernal-Mizrachi, unpublished observations). One of the 
mechanisms used for cell cycle regulation by Akt is the phosphorylation and inhibition of 
glycogen synthase kinase 3β (GSK3β), which results in direct regulation of some main cell 
cycle regulators such as cyclin D1, c-Myc, β-catenin (Chang et al., 2003) and  p21.  
Akt/PKB also regulates cell cycle by phosphorylation and inactivation of the Foxo family of 
forkhead transcription factors (AFX/Foxo4, FKHR/Foxo1, and FKHR-L1/Foxo3a) 
(Martinez-Gac et al., 2004), even in this case leading to the regulation of a specific cell 
cycle player:  p27kip1 (Chang et al., 2003). In particular the PI3K-Akt/PKB pathway elicits 
events that reduce the abundance of p27Kip1 by regulation of transcription, translocation 
and protein levels, indicating that this cell cycle inhibitor can contribute to β-cell failure 
during the development of type 2 diabetes in insulin resistant models (Uchida et al., 2005). 
Similar to p27Kip1, Akt/PKB phosphorylates p21CIP, thereby inducing cytoplasmic 
translocation and stabilization (Chang et al., 2003).  
Neogenesis of β-cells occurs from progenitor cells arising from pancreatic ducts, but 
the mechanism behind this observation remains unknown (Bonner-Weir, 2000). Although 
recent observations suggest that neogenesis is not a major contributor in the maintenance 
of adult β-cell mass (Dor, Brown, Martinez, & Melton, 2004),the role of neogenesis in 
regenerative conditions is still a matter of debate. Even in this mechanism induction of Irs2 
and Akt/PKB signaling could play a crucial role, since its activation in ductal cells of 
pancreatectomized mice has been associated to neogenesis (Jetton et al., 2001).  
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The Akt/PKB signaling is one of the critical pathways regulating cell survival, and its 
importance in β-cells has been suggested by increased apoptosis observed in Irs2−/− mice. 
In β-cells, Akt/PKB signaling mediates anti-apoptotic effects induced by diverse agents 
such as glucose, GLP-1, IGF-1, and insulin (Brubaker & Drucker, 2004; Dickson et al., 
2001, Srinivasan et al., 2002 and Wang et al., 2004); moreover the activation of Akt/PKB 
signaling protects β-cells against fatty acid-induced apoptosis and modulates survival to 
endoplasmic reticulum stress (Srinivasan et al., 2005 and Wrede et al., 2002). Glucose 
activation of Akt/PKB results in part by a paracrine/autocrine stimulation of the insulin 
receptor suggesting that glucose can be an important modulator of β-cell survival (Ohsugi 
et al., 2005). Akt/PKB affects survival by directly regulating members of the Bcl-2 family. 
Phosphorylation of BAD inhibits the pro-apoptotic activity by releasing it from the Bcl-2/Bcl-
X complex and binding to 14-3-3 proteins. Increased apoptosis was associated with 
decreased Bcl-XL and Bcl-2 expression in pdx1+/− islets, suggesting a potential link 
between Akt, pdx1, and survival (Johnson et al., 2003).  
The regulation of cell size by Akt/PKB is mediated by activation of the mammalian 
target of rapamycin (mTOR), which targets ribosomal S6 kinase (S6K) and eukaryote 
initiation factor 4E binding protein 1 (4EBP1), key regulators of protein translation and cell 
size. Mice deficient in S6k1 exhibited glucose intolerance and hypoinsulinemia associated 
with a 15% reduction in β-cell size, similar to the phenotype in dS6K-null Drosophila 
(Pende et al., 2000). Moreover, overexpression of a constitutively active form of Akt/PKB 
resulted in increased cell size suggesting that S6K1 relates some of the growth signals 
induced by Akt/PKB. The potential role of mTOR/S6K signaling in proliferation remains 
controversial. There is substantial evidence for a role of insulin/IGF signaling in insulin 
secretion. Experiments in insulinoma cells suggest that the regulation of insulin secretion 
by PI3K/Akt/PKB is complex and no consensus has yet been achieved, however reduction 
in Akt/PKB activity in β-cells by overexpression of a kinase-dead Akt/PKB mutant results in 
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an insulin secretory defect (Bernal-Mizrachi et al., 2004). This secretory dysfunction is 
similar to that observed in type 2 diabetes but the mechanisms are still unclear.  
 
Preventing diabetes: new strategies 
It has become apparent that a number of strategies for preventing the apoptosis of islets 
and preserving β-cell functions may have therapeutic relevance in preventing the 
pathogenesis of diabetes (Hui et al, 2004, Giannoukakis et al, 2002). To this aim, various 
molecules have been studied for their ability to regulate the cellular changes leading to 
apoptosis in β-cells. Recently, the IGF I / IGF BP3 complex has been recognized to 
enhance β-cell replication and β-cell survival after exposure to proapototic agents, which 
indicates this complex as a survival factor for β-cells undergoing apoptosis (Chen et al, 
2004). Glucagon-like peptide-1 (GLP-1) is a growth factor for β-cells, but it also has a 
powerful antiapoptotic action (Hui et al, 2003). The role of glucose is not still clear; 
however, a pathway activated by glucose and capable of enhancing β-cell survival against 
apoptosis has been studied (Srinivasan et al, 2002). Some other molecules, as cysteine 
(Rasilainen et al, 2002), carbon monoxide (Gunther et al, 2002) and the nuclear factor 
kappa B  (Chang et al, 2003) have shown similar protective properties during the apoptotic 
process in β-cells in vitro.  
The characterization of the specific apoptotic pathways involved in this disease has led to 
the individuation of various drugs able to mimic cell death occurring in diabetes. In our 
study we used streptozocin, S-Nitroso-N-Acetylpenicylamine (SNAP) and Hydrogen 
peroxide (H2O2) as models to study the putative antiapoptotic action of T3. As 
demonstrated by several studies, indeed, these agents are able to activate different 
apoptotic and necrotic pathways in β-cells in vitro (Chang et al, 2003; Oyadomari et al, 
2001; Rasilainen et al, 2002).  
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In recent years, numerous studies focused on promoting β-cell survival to counteract the 
β-cell mass decrease occurring in diabetes. Recent advances have indicated the signal 
transduction via insulin receptor substrate-2 (IRS-2) and downstream protein kinase B 
(PKB, also known as Akt) as critical to the control of β-cell survival. 
 
Might T3 play a role in promoting β cell survival ? 
Several factors (IGF 1, IGF 2, GLP-1, etc.), known for their proliferative properties and/or 
their action on cell differentiation, have also been shown to be capable of interfering with 
the sequence of events leading to cell apoptosis and of promoting cell survival 
(Giannoukakis et al, 2000; Jill et al, 2000; Perfetti et al, 2000). In this study we 
hypothesized that thyroid hormone T3 ─ whose effects on cellular proliferation are well 
known ─ might affect the regulation of specific apoptotic pathways in the insulin secreting  
cells rRINm5F and hCM.  Our evidences suggest the involvement of the PI3K pathway in 
mediating this novel survival action of T3; in particular we have shown that T3 is able to 
induce the phosphorylation of Akt in the islet cells hCM and rRINm5F (Verga Falzacappa 
et al. 2006). Additionally Cao et al. (2005) have demonstrated that T3 is specifically able to 
activate Akt in a nongenomic manner. Interestingly, this activation implies the recruitment 
of the thyroid receptor β1 by the PI3K, suggesting a mechanism similar to those identified 
for steroids. The PI3K expression is mainly cytoplasmic, and it might be possible that 
cytoplasmic or cell membrane-bound TRs are responsible for the recruitment of PI3K. 
Extranuclear TR expression, indeed, has been described long since (Davis  et al. 2000; 
Heery  et al. 1997; Zhu  et al. 1998).  
To examine the specific pathway via which T3 can activate Akt in pancreatic beta cells and 
to understand further the possible implication of a nongenomic action of T3 in these 
cellular systems, we suggest a specific role for a “cytoplasmic”  thyroid hormone receptor 
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β1 implicated in the PI3K pathway and able to mediate nongenomic actions of T3 in 
pancreatic beta cells.   
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Aim of the study 
A major contributing factor in the pathogenesis of both type 1 and type 2 diabetes is an 
acquired inadequateβ-cell mass that no longer is able to compensate for insulin resistance 
and/or insulin-secretory demand. Reduced β-cell mass in those cases is predominantly 
caused by an increased rate of β-cell apoptosis. Therefore, an anti-apoptotic means of 
promoting β-cell survival is conceivably a viable therapeutic approach to treat or even 
prevent the onset of type 1 and type 2 diabetes. To this aim several factors (IGF 1, IGF 2, 
GLP-1, etc.), known for their proliferative properties and/or their action on cell 
differentiation, have been shown to be capable of interfering with the sequence of events 
leading to cell apoptosis and of promoting cell survival (Giannoukakis et al, 2000; Jill et al, 
2000; Perfetti et al, 2000).Given the well known action of thyroid hormones on cellular 
processes such as mitogenesis and differentiation, and since we previously demonstrated 
(Misiti et al, 2005) a differentiative role for thyroid hormone T3 in pancreatic ductal cells, as 
β cell precursors; in this study we hypothesized that T3 might influence some cellular 
processes in pancreatic β cells. In particular, considering a possible mitogenic role for the 
hormone in these cells, we intended to verify whether an hormone treatment could 
counteract an apoptotic process ongoing in the insulin secreting  cells rRINm5F and hCM.  
The Protein Kinase B (Akt) in pancreatic β-cells plays a critical role in controlling β-cell 
growth and survival. Indeed, inhibition of PKB activation in β-cells is evidently linked to 
increased β-cell apoptosis.  As such, a therapeutic strategy to alleviate insulin resistance 
by preventing inhibition of IRS/PI3K/PKB signaling should also have the added bonus of 
promoting β-cell survival. To this aim we decided to investigate the involvement of this 
crucial factor in the T3 survival action on β cells, and further to analyze the mechanisms 
underlying the relationship between thyroid hormones and Akt in pancreatic β cells. 
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Aim of the study 
Aim of this study was to investigate the effect of T3 treatment on pancreatic β cells, in 
particular to analyze the ability of T3 to affect β cell proliferation and survival when a 
diabetes-like apoptosis is induced and to characterize the specific molecular targets and 
pathways involved.  
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Materials and Methods 
 
3,5,3’-triiodothyronine (T3) was obtained from Sigma-Aldrich (St. Louis, MO, USA). BrdU, 
Hoechst, streptozocin, S-Nitroso-N-Acetylpenicylamine (SNAP), H2O2, LY-294,002 
hydrochloride, PD098059,  Bisphenol-A dimethacrylate (BPA) and cycloheximide (CHX)  
were obtained from Sigma-Aldrich; Rp-cAMP was purchased from Calbiochem (La Jolla, 
CA). 
 
Cell Culture 
Human insulinoma cell line CM was obtained from Dr. MG Cavallo (Baroni et al, 1999; 
Cavallo et al, 1996); rat insulinoma cell line RINm5F (Cat. No. CRL-11605) was purchased 
from ATCC (American Type Culture Collection, Manassas, VA, USA). 
rRINm5F cells were cultured in RPMI 1640 (ICN, Eschwege, Germany) complemented 
with 10% Fetal Bovine Serum (ICN); hCM cells were cultured in RPMI 1640 (ICN) 
containing 5% FBS; all cell culture media were supplemented with L-Glutamine 2 mM 
according to manufacturer’s instructions, and Penicillin 100 µg/ml-Streptomycin 50 µg/ml. 
Cells were maintained at 37°C under humidified condition of 95% air and 5% CO2. 
To determine the effects of T3 on cell proliferation, cells were cultured to 60% confluence 
and exposed to the hormone T3 or to vehicle alone after 12h. Every 24 hours, fresh 
aliquots of T3 (10-3M) were added to culture medium in all the experiments.  
In the apoptosis studies, cells were plated in a 96 well plate, and after 12h the hormone T3 
or vehicle alone were added to culture medium; the cells were then exposed to 
streptozocin (15mM) for 2 hours, SNAP (200µM) for 24h and H2O2 (50 µM) for 30 min. in 
the presence or the absence of the thyroid hormone T3 10-7M.  
To investigate the specific pathways via which T3 exerts its antiapoptotic and proliferative 
effect, cells were exposed singly to each inhibitor, i.e., LY-294,002 hydrochloride 50 µM 
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(PI-3 K inhibitor), PD098059 50 µM (MAPK inhibitor),  Rp-cAMP 50µM (PKA inhibitor) and 
Bisphenol-A 10 µM (T3 analogue), added only once at the beginning of the individual 
experiments. Each inhibitor has been utilized as previously described by Hui et al, 2003 
and Moriyama et al, 2002. 
Streptozocin and H2O2 were solubilized and diluted in water immediately before performing 
each experiment. T3, SNAP, LY-294,002, PD098059, Rp-cAMP and Bisphenol-A were  
resuspended in stock  solution,  according  to  manufacturer’s instructions,  and  stored  at 
-20°C. Control cultures were grown under the same culture condition as treated cells, but 
in the absence of drugs. The final concentrations of NaCl2 0.95%, methanol, ethanol and 
dymethylsulfoxide were identical in every culture, irrespective of the particular treatment 
group. 
To determine the effects of T3 (10-7M) on Akt activation in the cell lines, cells were cultured 
to 60% confluence and after 12h exposed to the hormone T3, LY-294,002 hydrochloride 10 
µM, Bisphenol-A 100 nM, 1µM, 10 µm, TRIAC 100 nM, 1µM, 10 µM, CHX 3 mM added 
only once, at the beginning of the individual experiments.  Each inhibitor has been utilized 
as previously described by Hui et al, 2003, Moriyama et al, 2002 and LY-294,002, 
Bisphenol-A and TRIAC were  resuspended in stock solution, according to manufacturer’s 
instruction, and stored –20°C. Control cultures were grown under the same culture 
condition as treated cells but in the absence of drugs. The final concentration of methanol , 
ethanol and DMSO were identical, in every culture, irrespective of the particular treatment 
group. 
 
RNA Isolation and RT-PCR Analysis 
Total cellular RNA was isolated from rRINm5F cells by using Total RNA Isolation kit 
(Promega, Madison, WI), according to the manufacturer’s protocol. RNA (2 µg) was then 
subjected to reverse transcription (RT) by using a cDNA synthesis kit OmniScript 
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(QIAGEN, Chatsworth, CA). Amplification was performed, after a first denaturing step at 
94°C for 5 min., for 30 cycles for the cell-cycle-related molecules (cyclins A and D1, p27) 
and 23 cycles for β−Actin, at a denaturing temperature of 94° for 1 min., at annealing 
temperature (Table 1) for 1 min. and at an extension temperature of 72° for 30”. PCR 
products were electrophoresed onto a 1.5% agarose gel containing ethidium bromide (0.5 
µg/ml) and visualized under UV light. The relative intensity of the bands was quantitated by 
densitometric analysis (Total Lab, Nonlinear dynamics, New Castle, UK) and normalized to 
the co-amplified β−Actin cDNA fragments. Oligonucleotide primers used in these 
experiments are presented in Table 1.  
  
Immunofluorescence Microscopy 
Cells were plated onto multichamber slides (BD Falcon) and culture for 72 hours for Insulin 
staining or for 12 hours and then exposed to the hormone treatment for the indicated times 
f or the other protein staining. Slides were washed in PBS 1x, (CAMBREX) air-dried, fixed 
and permeabilized with acetone/methanol (1:1 vol/vol stored at -20°) for 10 min., and then 
rehidrated in PBS 1x. Slides were then incubated with 20% fetal bovine serum in PBS 1x 
for 20 min. and washed three times in PBS 1x. Thereafter slides were stained with primary 
antibodies (rabbit-anti-PI3K Sta. Cruz, mouse anti TRβ1 Sta. Cruz, mouse anti Akt Sta. 
Cruz, rabbit anti Phospho Akt 1/2/3- Ser 473 Sta. Cruz) at a dilution of 1:100, for 45 min at 
RT in a humid chamber. After three washes in PBS 1x, slides were incubated with 
secondary antibodies (FITC conjugated rabbit anti-mouse IgG, TRITC conjugated rabbit 
anti mouse IgG, TRITC conjugated swine anti-rabbit IgG, DAKO,Denmark) for 45 min at 
room temperature in dark, at a dilution of 1:40. Immunofluorescence analyses of cell slides 
was carried out using an inverted fluorescence microscope equipped for confocal 
microscopy (Olympus Flowview FV500). Images were processed by the Adobe Photoshop 
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software.Negative controls including omission of the primary antibody were also 
performed.  
 
Cell Growth 
Cell growth was analyzed by determining Trypan Blue negative cell number in a Thomas’s 
hematocytometer. Rat RINm5F and human CM cells were plated as a monolayer at a 
density of 4 x 104 and 2.5 x 104 , respectively, in 6 multiwells. After 12h, they were 
exposed to different doses of T3 (10-9,10-7,10-11 M) or to vehicle alone. At 24, 48 and 72 
hours of continuous exposure, viable cells were harvested and counted. Cell number was 
determined, and data presented as means ± SD.  
The effect of T3 on cell growth was quantified by assuming that the considered populations 
were showing exponential growth. The increase in cell numbers was analyzed by fitting to 
the exponential growth equation:  
     ln(N) = ln (N0) + kt 
where N = cell number at time t,  N0 = cell number at t0, K = growth constant 
The doubling time td, is given by: 
     Td = ln (k)/0.963 
 
MTT Assay 
Cell proliferation was studied by MTT assay (Promega). Cells were plated in 96 multiwells 
at a 70% confluence. After 12h, cells were exposed to drugs and T3 for the indicated 
times. A solution of a tetrazolium salt was added to the culture medium and, after 3h, the 
metabolic formazan product was solubilized in an organic solution. After 1h of 
solubilization, the absorbances at 570 and 630 nm were recorded by using a 96 well plate 
reader.  
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BrdU Staining 
Cell proliferation was determined additionally by BrdU staining. Cells were plated at a 70% 
confluence onto a multichamber slides (BD Falcon) and then cultured in the presence of T3 
or vehicle alone; during the last 30 min. of the hormone treatment, cells were incubated 
with BrdU 10µM (Sigma). The slides were then air-dried and cells were fixed in ethanol 
70% for 30 min. at 4°C. Slides were then washed in PBS 1x  (ICN) and incubated with HCl 
3N for 25 min. at RT; the reaction was then neutralized with borax-borate buffer (pH 9.1), 
and slides were washed in PBS 1x. Slides were incubated sequentially with PBS 1x, FBS 
20%, Tween 20 0.5% for 15 min. at RT, and then with mouse monoclonal antibody anti- 
BrdU (Roche Diagnostic) 1:200, for 1 hour at room temperature. After three washes in 
PBS 1x, slides were incubated with the secondary antibody anti-mouse TRITC conjugated 
(Dako), 1:40, for 1h at room temperature in dark. Slides were then washed in PBS 1x twice 
and stained with Hoechst 1 µg/ml for nuclear detection. Localization and intensity of 
fluorescence were observed with a fluorescent microscope (Leika). Images were taken by 
a Canon Digital Camera and processed by the Adobe Photoshop software. Negative 
controls including omission of the primary antibody were also performed.  
 
TUNEL Assay 
Tunel assay was performed by using the In situ Cell Death detection kit (Roche, Basel, 
CH). 
Cells were plated at a 70% confluence onto multichamber slides (BD Falcon) and then 
exposed to specific drugs and to the hormone. After the removal of the culture medium, 
the slides were washed in PBS 1x (ICN) and fixed in paraphormaldeide 4% in PBS 1x for 
30 min. at Room Temperature. The slides were then washed in PBS 1x and incubated in 
triton 0.1 % in Sodium Citrate 0.1 % for 2 min. on ice; the slides were then washed in PBS 
1x and air-dried. The slides were incubated with the Tunel mixture according to 
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manufacturer’s instructions, for 1h, at 37°C in dark; then samples were washed and 
counter-stained with Hoechst (1 µg/ml). Tunel positivity was visualized with a Leika 
(Germany) fluorescence microscope and the images were taken by a Canon digital 
camera. 
 
Western Blot Analysis 
Approximately 3x106 cells were lysed for 30’ at 4°C in buffer containing 1% Tween 20, 10% 
glycerol, 150 mM NaCl, 50 mM Hepes pH 7.0, 1 mM MgCl2, 1 mM CaCl2, 1 mM NaF, 10 
mM Na4P2O7, 2 mM NaVO3, 1 mM Phenylmethylsulfonyl fluoride, protease inhibitors. The 
lysates were centrifuged at 12,000 rpm for 30’ and the total cellular protein content was 
measured by using the Bradford method (Bio-Rad, Richmond, CA). Cytosol-nuclear 
protein separation was obtained by nuclear/cytosol fractionation kit (MBL, International 
Corporation Woburn, MA, US) following manufacturer’s instruction. 40 ÷ 60 µg of total 
extracts and 30 µg of nuclear or cytosol proteins per sample were loaded onto a 10-12% 
SDS-polyacrylamide gel, electrophoresed, and then blotted onto PVDF membranes (Bio-
Rad). As a loading control, proteins were stained with Ponceau. Filters were blocked for 
non-specific reactivity by incubation for 1h at RT in 5% non-fat dry milk dissolved in PBS 
1x, Tween 20 0.1 %, and then incubated for 16h at 4°C, with: TRα1 (S.ta Cruz 
Biotechnology, Inc., San Diego, CA., 1:500), TRβ1 (S.ta Cruz 1:500), Cyc A (S.ta Cruz, 
1:200), Cyc D1 (BD Pharmingen, Franklin Lakes, NY, USA, 1:250), Cyc E (BD 
Pharmingen, 1:250), p27 (BD Pharmingen, 1:500), Bax (BD Pharmingen, 1:500), Bad (BD 
Pharmingen, 1:500), Caspase 3 (S.ta Cruz, 1:500), Bcl-2 (S.ta Cruz, 1:500), Bcl-XL (BD 
Pharmingen, 1:500), Akt (Sta. Cruz, 1:500), Phospho Akt 1/2/3-Thr 308 (S.ta Cruz, 1:200), 
Phospho Akt 1/2/3-Ser 473 (Sta. Cruz, 1:500), GSK3α (S.ta Cruz, 1:500), pGSK3-α-Ser 9 
(S.ta Cruz, 1:500), and Histone H1 (Sta Cruz, 1:1000), and 1h at RT with β-Actin (Sigma, 
St. Louis, MO, USA 1:1000) and α-tubulin (Sta. Cruz, 1:1000) ─ diluted in 5% milk, PBS 
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1x, Tween 20 0.1% . After three washes in PBS 1x, Tween 20 0.1%, the membranes were 
incubated for 45 min. with the secondary HRP antibodies (anti-goat, anti-mouse, anti-
rabbit - Sigma) 1:4000 in milk 5%, PBS 1x, Tween 20 0.1% for 45’ at RT. Immunoreactivity 
was visualized by the ECL immuno-detection system (Amersham Corp, Arlington Heights, 
IL), following manufacturer’s instructions.  
The relative band intensity was evaluated by densitometric analysis (Totallab, Nonlinear 
dynamics) and normalized to β-actin. 
 
Immunoprecipitation 
Cells were lysed in 1% NP40, PMSF 0,2mM, NaF 10mM, pepstatin 0,7µg/ml, aprotinin 
25µg/ml in PBS1X. After 10’ on ice, samples were sonicated and centrifuged at 12000 xg 
for 15’. The total cellular protein content was measured using Bradford method (Bio-Rad, 
Richmond, CA, USA). 400 µg of cell lysate were incubated for 2h with 30µl G-protein 
(Roche Diagnostics, Basel, CH). 
After preclearing, the extracts were incubated overnight at 4 oC with mouse anti TRβ-1 
antibody (Sta. Cruz, 1 µg) and 30µl freshly prepared G-protein. The immunoprecipitates 
were electrophoresed onto an 8% SDS-Polyacrilamide gel, and blotted onto PVDF 
membrane (Biorad). The membranes were blocked with 5% non-fat dry milk in PBS1X-
Tween 20 0,1% for 1h at room temperature and probed with rabbit anti PI3K-p85α (1:500) 
or anti PI3K-p110 (1:500), and afterwards with mouse anti-TRβ1 antibody (Sta. Cruz, 
1:500) diluted in 5% non-fat dry milk in PBS1X-Tween 20 0,1% overnight at 4oC under 
gentle rocking. After washing in PBS 1X-Tween 20 0,1%, the membranes were incubated 
with the secondary antibody HRP conjugated (anti-mouse Sigma, anti-rabbit Sigma) 
1:4000 in 5% milk, PBS1X, Tween 20 0,1%, for 1h at RT. Immunoreactivity was visualized 
by the ECL immuno-detection system (Amersham Corp.) following manufacturer’s 
instructions.  
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PI3K kinase assay 
Cells were grown on 100 mm dishes and exposed to T3 10-7M, LY 10 µM or vehicles alone 
for 30 min. At the end of the treatment cells were lysed and PI3-K activity was estimated 
using a commercially available PI3-K ELISA kit (Echelon Biosciences, Salt Lake City, UT) 
according to the manufacturer's instructions. Protein A beads were then utilized for the 
PI3-kinase ELISA (Echelon Biosciences Inc, Salt Lake City, UT) following manufacturer’s 
instruction. Briefly, cells were lysed with a low stringency buffer and 100 µg of lysates were 
incubated with 1 µg of TRβ1 antibody for 1h at 4°C . Then protein G-agarose beads were 
added to equal amounts of total protein, and the samples were rocked (4°C) for 16 h. The 
immunoprecipitated TRβ1 were incubated with phosphatidylinositol 4,5-bisphosphate 
substrate and reaction buffer for 1 h 30 min. The amount of PIP3 formed from 
phosphatidylinositol-4,5-bisphosphate by PI3-K activity was detected using a competitive 
ELISA. The obtained OD values were inversely proportional to the amount of PI(3,4,5)P3 
produced by PI3-K activity . Enzyme activity was estimated by comparing the values from 
the samples to those in the standard curve. 
 
RNA interference 
Cells were plated onto 6 multiwells and grown in complete medium, after 24h cells were 
transfected with siRNA SmartPool THRB (Dharmacon, Lafayette, CO, US). Transfection 
was performed by incubating cells with 200 pmol of siRNAs in 2 ml of serum free 
transfection medium using Lipofectamine reagent (Invitrogen, Carlsbad, CA, USA). After 
3h of incubation, normal medium supplemented with serum replaced transfection medium 
and cells were grown for 30h before starting T3 treatment. Subsequently cells were lysed 
for Western Blot analysis and samples were analyzed as described  
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Statistical Analysis 
The data were presented as means ± SD. A comparison of the individual treatment was 
conducted by using Student’s t test or, if there were more than two groups, by one-way 
ANOVA , followed by Dunnett or Tukey post-hoc analyses.  A P value <0.05 was 
considered significant. 
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T3 induces cell growth and proliferation in islet β-cells and provokes a shortening of the 
cellular doubling time 
The presence of the thyroid receptor isoforms TRα1, TRα2 and TRβ1 and the ability to 
synthesize insulin have been verified in the insulinoma cell lines rRINm5F and hCM cells. 
As a first step towards the understanding of the effect of T3 on insulin secreting cells, we 
examined the effect of T3 on the growth of rRINm5F and hCM cells by culturing the cells in 
the presence or the absence of the hormone treatment. 
Cells were treated for three days with different concentrations (10-7, 10-9 and 10-11 M ) of T3 
added every 24h. The number of harvested viable cells was determined, as shown in 
Figure 1, panels a (rRINm5F) and b (hCM), by counting in a Thoma’s hematocytometer. 
While the dose 10-11 M did not affect the cell growth neither in rRINm5F or in hCM cells, 
the doses  10-9  and  10-7 M promoted cell growth in both the cell lines. The dose 10-7 M 
showed the highest effect and was chosen for the following experiments. In the Figure 1, 
panel a, rRINm5F is shown to grow with a doubling time of approximately 30h (calculated 
as described in Materials and Methods) in the absence of T3. However, the addition of T3 
in the culture medium led to the stimulation of the cell growth with a doubling time of 
approximately 20h. The hCM cells showed the same behaviour after treatment with T3, 
(Figure 1, panel b). Even in this case, the doubling time of the cell line seemed to be 
affected by the T3 (10-7M) treatment after the first 24h. All the treated cells showed a 
doubling time of approximately 18h, while the doubling time of the cells cultured in the 
absence of T3 was 24h. As shown in the Figure 1, panel c, the stimulatory effect of T3 (10-
7M) on cell growth reached a maximum on the 3rd  day (72h) of treatment (55% on 
RINm5F, and 45% on CM cells).  
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To further analyze the effects of T3 observed by cell growth analysis, MTT assay was 
performed in the first 2 days (48h) of treatment to investigate the putative proliferative 
action of T3. In the Figure 2, panels a (rRINm5F), and c (hCM), cell proliferation data are 
expressed as cell viabilities. As shown, the T3 treatment causes an increment of 10 % 
(rRINm5F) and of 15% (hCM) in the OD value already after a 6-h treatment. Such increase 
reached a maximum of 30% (RINm5F) and 35% (CM) after 24h. These data ─ expressed 
as the increase on the control absorbance value (taken as 100%) ─ were consistent with 
the cell counting data, which confirms that thyroid hormone T3 had a proliferative effect on 
both the cell lines. 
This effect was further confirmed by BrdU staining experiments. As shown in the Figure 2,  
when cells from both rRINm5F (panel b) and hCM  (panel d) were cultured in the presence 
of T3, the majority of nuclei were positive for BrdU. On the contrast, a little number of  
positive nuclei was visualized in the cells cultured in the presence of vehicle alone, which 
demonstrates that T3 induced the DNA sinthesis in RINm5F and CM cells after 24 and 48h 
of treatment.  
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Figure 1 T3 causes an increment in the growth rate of RINm5F and CM cell lines  
RINm5F (a) and CM (b) were grown as a monolayer and exposed to different thyroid 
hormone concentrations (10-7, 10-9 and 10-11M). The graphic shows the effect of the T3 
treatment on the cell growth determined by counting Trypan Blue negative cells. y axis: cell 
number, x axis: hours of T3 treatment. c. The percentage of induction (+T3/-T310-7M) on 
cell growth is shown. The effect on RINm5F cells is shown in grey ◊, while the effect on CM 
cells is shown in black ■.
All the data are presented as means ± SD and are the results of three individual 
experiments at least. A comparison of the individual treatment was conducted by using 
one-way ANOVA followed by Tukey post-hoc test. 
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Figure 2 T3 has a proliferative effect on RINm5F and CM cells 
MTT assay and BrdU staining on RINm5F (a,b) and CM (c,d) cells are shown. 
MTT assays: The cells were grown in 96 multiwells and exposed or not to T3 10-7M for the 
indicated times (x axis). Cell viabilities are expressed (y axis) as % of the OD (570 nm) control 
value (taken as 100%). * = P < 0.05; ** = P< 0.01. A P value <0.05  was considered significant. 
Black: T3 treated cells, grey: control cells  
All the data are presented as means ± SD and are the results of three individual experiments at 
least. A comparison of the individual treatment was conducted by using Student’s t test. 
BrdU staining: Cells were grown onto multichamber slides and exposed or not to T 3 10-7M  for 
24 and 48h. Cells were incubated with BrdU for the last 30 min. of theT3 treatment and then 
immunostained for BrdU (in red). Nuclei were counter-stained with Hoechst (in blue). 
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T3 increases the gene and protein expression of cyclins A, D1 and E and decreases the 
expression of the CDKI p27Kip1 
We measured the protein levels of the key regulators of the G1-to-S-phase progression, 
such as cyclins A, D1 and E after treatment with T3. The kinase activity of a cyclin-cdk 
dimer is regulated mainly by changes in the protein levels of the cyclin component during 
the progression through the cell cycle. Cyclin A, D1 and E protein levels increase at the 
G1- to-S-transition and are important for the cell cycle progression from the G1-to-S-phase 
(Morgan, 1997). As shown by Western Blot analyses (Figure 3, panel a), the hormone 
treatment  (T3 10-7 M) caused an increase in the cyclins A and D1 protein levels, for the 
indicated times, leading to a maximum of 50% (Cyc A) and 40% increases (Cyc D1) after 
24h in rRINm5F cells. The cyclin E protein levels (Figure 2, panel a) were upregulated (20-
30 %) by 24- and 48-h T3 treatments, while the 6-h hormone treatment didn’t seem to 
affect the protein expression. 
Moreover, we examined the effect of the T3 treatment on the expression of the CDK 
Inhibitor p27Kip1, which controls the progression through the cell cycle via inhibition of the 
cdk subunit. As shown in the Figure 3, panel a, the 24h and 48h hormone treatments 
caused a 70 % and a 50 % decrease of p27 in the protein expression, respectively. These 
data suggested that the proliferative effect of the thyroid hormone T3 could depend on a 
direct regulation of the cyclin and p27 protein levels. 
Western Blot analyses (Figure 3, panel b) revealed also that in the human insulinoma cell 
line hCM the T3 treatment prompted an upregulation in the protein levels of cyclins A, D1 
and E, while the protein levels of p27 resulted downregulated by T3, for the indicated times 
(6, 24 and 48h).  
Since the T3/TR complex is able to regulate the gene expression (Yen, 2001), we 
investigated whether the cycle-related molecules were regulated even at mRNA level. RT-
PCR experiments have been performed only in rRINm5F, which have been widely used as 
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a β-cell model in vitro and largely investigated in their cytological and molecular 
characteristics. The Figure 4, panel c, shows that all the cycle-related molecules we have 
analyzed (Cyclins D1, E and p27) were regulated by T3, as measured by densitometric 
analyses of RNA levels. Particularly, the hormone treatment led to maximum 50% (Cyc E) 
and 100% (Cyc D1) increases after 48h, compared to the untreated samples. The p27 
gene expression was downregulated by 6h, 24h and 48h hormone treatment, reaching a 
50% maximum decrease after 24h.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
36 
Figure 3
rRINm5F
a
6h             24h          48h        
C      T        C     T      C      T
CycA
Cyc D1
Cyc E
P27
B-actin
0
50
100
150
200
c 6h 24h 48h
time (hours of treatment)
%
 o
f c
on
tro
l
control CycA Cyc D1 Cyc E p27
6h             24h          48h        
C      T        C     T      C      T
CycA
Cyc D1
Cyc E
P27
B-actin
b
0
50
100
150
200
c 6h 24h 48h
time (hours of treatment)
%
 o
f c
on
tro
l
control CycA Cyc D1 Cyc E p27
* ****
hCM
** ****
37
rRINm5F
c
6h       24h       48h         
C   T    C  T       C  T
Cyc D1
Cyc E
P27
B-actin
0
50
100
150
200
c 6h 24h 48h
time (hours of treatment)
%
 o
f c
on
tro
l
control Cyc D1 Cyc E p27
** ****
Figure 4 T3 affects mRNA and protein expression of the main cycle-related molecules in 
RINm5F and CM cells
Western Blot analyses for cyclins A, D1 and E, p27Kip1 and β-actin on RINm5F (a) and CM (b) 
cells are shown. Cells were grown in the presence of T3 10-7M or of vehicle alone for the 
indicated times. Western Blot analyses were performed as described in Materials and Methods 
and a specific band was detected for each analyzed molecule. c. RTPCR for cyclins D1 and E, 
and p27 were performed on RINm5F cultured in the presence or the absence of T3 10-7M for 
the indicated times, as described in Materials and Methods. Densitometric absorbance values 
from three separate experiments were averaged (± SD), after they had been normalized to β-
actin for equal loading. Data are presented in the hystogram as percentages (y axis), using 
control as baseline (100%). x axis: hours of T3 treatment. All the data are presented as means 
± SD and are the results of three individual experiments at least. A comparison of the individual 
treatment was conducted by using Student’s t test. * = P< 0.05; ** = P < 0.01. A  P value <0.05  
was considered significant (control: black; Cyc A: white; Cyc D1: light grey, Cyc E: black; p27: 
dark grey). 
38
Results 
The proliferative effect of T3  is thyroid hormone receptor-mediated 
Given the results obtained for the cell cycle molecules mRNA, and since the transcription 
regulation happens through the T3/TR action, we decided to investigate whether a T3 
antagonist could affect the T3 proliferative effect. The thyroid hormone receptor antagonist 
Bisphenol A ─ that is, a thyroid hormone analogue capable of disrupting the action of the 
said hormone through the thyroid hormone receptor (Moriyama et al, 2002) ─ was utilized 
in MTT experiments to study the specificity of the T3 proliferative effect. The cells were 
plated in 96 multiwells and exposed respectively to T3 (10-7M), BPA (10µM), vehicles alone 
and concurrent to T3 and BPA, for 24h.  As shown in the Figure 4 the addition of BPA (10 
µM) to the culture medium led to a blockade of the proliferative effect of T3 on both the cell 
lines. The viability values of the cells exposed to T3 and BPA for 24h were comparable 
with the values of the control cells. The adding of BPA alone to the cell cultures did not 
affect the cell viability (data not shown). These data suggested that the proliferative effect 
of T3 might involve the binding of the hormone to its receptors. 
Taken together these results suggested that the regulation of the cell cycle-related 
molecules observed by us might be due to a direct effect of the T3/TR complex . 
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Figure 3 The T3 proliferative effect is TR-mediated
RINm5F (a) and CM (b) cells were immunostained for Insulin. 
Cells (both RINm5F and CM) were grown in the presence of T3 10-7M or of vehicle alone for 
the indicated times. Western Blot analyses for TR α1 and β1 were performed as 
described in Materials and Methods and a specific band was detected for each 
analyzed  isoform. Densitometric absorbance values from three separate experiments 
were averaged (± SD) after they had been normalized to β-actin for equal loading. Data 
are presented in the hystogram as percentages (y axis),  using control as baseline 
(100%). x axis: hours of T3 treatment (control: black; TRα1: white; TRβ1: grey).  * = P< 
0.05; ** = P < 0.01. A  P value <0.05  was considered significant.
c. RINm5F and CM cells were cultured in the presence or the absence of T3 (10-7M) and 
concurrently exposed or not to Bisphenol A (10µM) for 24h. MTT assay results are 
presented as % of the OD (570 nm) control value (taken as 100%). T3 + BPA (black); 
T3 (grey); control (white). All the data are presented as means ± SD, and are the 
results of three independent experiments at least. A comparison of the individual 
treatment was conducted by using Student’s t test. * = P< 0.05; ** = P < 0.01. A  P 
value <0.05  was considered significant.
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T3 protects insulinoma cells from pharmacological induced apoptosis 
Since many growth factor with well charachterized mitogenic actions have been related to 
specific survival effect, and given the existence of common player in proliferation and 
survival pathways, we decided to verify if T3 could also affect the survival of the islet β-
cells exposed to proapoptotic agents. To this aim apoptosis was induced by selected 
proapoptotic drugs in the cells exposed to T3 or to vehicle alone. The rRINm5F and hCM 
cells were treated with H2O2 50µM for 30 min., SNAP 200µM for 24h and streptozocin 
15mM for 2h. As shown in the Figure 5, panels a-b, the TUNEL assay was positive in the 
majority of the cells treated only with drugs (rRINm5F panels a: C,E,G; hCM, b: C,E,G), 
which demonstrates the presence of apoptosis, while in the cells treated with T3 (rRINm5F 
panel a: D,F,H; hCM, panel b: D,F,H) a minimally positive TUNEL results in a much weaker 
fluorescence, which suggests that the hormone T3 is able to counteract the proapoptotic 
action of the drugs.  
For both the analyzed cell lines, control cells cultured without drugs (rRINm5F, panel a: 
A,B; hCM, panel b: A,B) showed the absence of fluorescence positive nuclei.  
The effect on cell metabolism, which is highly affected in the presence of apoptosis, was 
confirmed by MTT assays (Figure 5, panel c). Cell viability was highly affected by the 
pharmacological treatment, causing a decrease of up to 40% (streptozocin) compared to 
the control OD value. In particular, the H2O2 treatment caused a decrease of 25% in both 
the cell lines, while SNAP caused a reduction of 40% (rRINm5F) and of 37% (hCM) in the 
cell viability values. The treatment with the thyroid hormone T3 10-7M added before the 
exposure to H2O2  and  streptozocin as well as during the exposure to SNAP prevented cell 
mortality and promoted cell survival. As shown in the Figure 5, panel c, the OD value in the 
cells pre-treated with the hormone and exposed to proapoptotic drugs was 90-100% of 
controls.  
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Interestingly, the antiapoptotic effect of T3 on cells exposed to H2O2 and streptozocin was 
not present if the cells were exposed to the thyroid hormone immediately after the 
treatment with the drugs (data not shown), which suggests that the hormone treatment can 
activate a survival response when it is administered concomitantly to proapoptotic drugs. 
We can speculate that this action might be due to the capability of the hormone to regulate 
some intrinsic factors of the cells, as demonstrated hereafter, thus contrasting an apoptotic 
cascade on-going.  
 42
Figure 5
+
-
-
-
+
-
C E
c e
TUNEL ASSAY
-
-
-
A20µm-
-
-
+
G
g
H2O2
SNAP
STR
a
-T
3
rR
IN
m
5F a
B
b
D
d
H
h
F
f
+ 
T3
b
A C
c
GE
e
-T
3
a g
hC
M
33
5
b
B
d f h
D F H
+ 
T3
43
c0
50
100
control H2O2 H2O2+T3 SNAP SNAP+T3 STR STR+T3
ce
ll 
vi
ab
ili
ty
(%
)  
   
 .
rRINm5F hCM
** **
**
Figure 5 T3 protects RINm5F and CM cells from pharmacological apoptosis
Tunel assay on RINm5F cells (a uppercase-letter panel) and CM cells  (b uppercase-letter 
panel.). Cells were cultured in the presence (b,d,f,h) or the absence (a,c,e,g) of T3 10-7M 
and exposed to different drugs (H2O2  c,d; SNAP e,f; streptozocin g,h). Apoptotic nuclei 
were detected as Tunel-positive only in the cells exposed to drugs alone (panels c,e,g). 
Nuclei were counter-stained with Hoechst (lowercase-letter panel). At least ten fields per
chamber and three independent cultures were examined.  c. MTT assays were performed 
on RINm5F (black) and CM (white) cells cultured in the presence or in the absence of T3 
(10-7M), and exposed to different drugs (indicated on the x axis). Data are presented as % 
of the OD (570 nm) control value (taken as 100%) on the y axis, as means ± SD, and are the 
results of at least five independent experiments. A comparison of the individual treatment 
was conducted by using one-way ANOVA followed by Dunnett post-hoc test. 
* = P< 0.05; ** = P < 0.01. A  P value <0.05  was considered significant.
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T3 prevention of apoptosis is associated with an increase of cellular antiapoptotic proteins 
and with a decrease of proapototic proteins 
An additional set of experiments was carried out to confirm the ability of T3 to counteract 
pharmacologically induced apoptotic cell death in rRINm5F and hCM cells. The 
observation that T3 was able to promote cell survival only when it was administered before 
the drug treatment supported the hypothesis that the hormone might act by enhancing the 
expression of endogenous antiapoptotic factors or by decreasing the expression of 
proapoptotic proteins. 
Western Blot analyses on rRINm5F (Figure 6, panel a) and hCM cells (Figure 6, panel b) 
revealed that the T3 treatment induced an upregulation of the antiapoptotic proteins Bcl-XL 
(in the cells exposed to H2O2 and streptozocin) and Bcl-2 (when cells were treated with 
H2O2 and SNAP), while the proapoptotic factors Bax and Bad were downregulated by T3 in 
the cells exposed to streptozocin and SNAP (Bax) and to streptozocin, SNAP and H2O2 
(Bad) in both the examined cell lines. All the analyzed proteins were regulated by the T3 
treatment even when the cells were not exposed to drugs, which suggests that the 
blockade of apoptosis we have observed (Figure 5) was due to a modulation of 
endogenous pro- and anti- apoptotic factors and occurred according to the inability of the 
hormone treatment to counteract apoptosis when it was administered immediately after the 
drugs (data not shown). 
The protein expression of the active proapoptotic Caspase 3, which is an upstream 
regulator of PARP cleavage, was downregulated by the hormone treatment when the cells 
had been exposed to H2O2, SNAP and streptozocin. These data suggest that the thyroid 
hormone T3 is able to counteract cell death by regulating the different molecular targets 
involved in the apoptotic cascade activated by different proapoptotic stimuli.
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Figure 6 T3 regulates the protein expression of the major pro- and anti-apoptotic factors in RINm5F 
(a) and in CM (b) cells.
Cells were grown in the presence or the absence of T3 10-7M for 24h and concurrently exposed to 
H2O2 (50 µM, 30min) or SNAP (200 µM 24h), or to streptozocin (15 mM 24h). Western Blot 
analyses were performed as described in Materials and Methods and a specific band was detected 
for each analyzed factor. Densitometric absorbance values from three separate experiments were 
averaged (± SD), after they had been normalized to β-actin for equal loading. Data are presented 
in the hystogram as percentages (y axis), using control as baseline (100%). The different 
experimental groups are indicated on the x axis. All the data are presented as means ± SD and are 
the results of three individual experiments at least. A comparison of the individual treatment was 
conducted by using one-way ANOVA followed by Dunnett post-hoc test. * = P< 0.05; ** = P < 0.01. 
A  P value <0.05  was considered significant.
(control: light grey ; Bax: dark grey, Bad: light grey, Casp3: horizontal stripes, Bcl-2: white, Bcl-XL: 
black). 
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T3 promotes β-cell survival through the PI-3 kinase/Akt signalling pathway 
Once T3 was determined as capable to promote cell survival in rRINm5F and hCM cells, 
the signal transduction pathways involved in this process were investigated. In islet β-cells 
the activation of several serine-threonine kinases ─ including MAP Kinases and PI-3 
Kinase ─ have been shown to be involved in cell survival (Franke et al, 2003). We 
investigated the role of the protein kinases PI-3 K and MAPK in the prevention of 
apoptosis. The cells were incubated in the presence or the absence of the MAPK inhibitor 
PD-98059 (50µM), or of the PI-3 kinase inhibitor LY-394002 (50µM), and exposed to the 
proapoptotic agents. As shown in the Figure 7, panels a (cells exposed to H2O2), b (SNAP) 
and c (streptozocin), MTT assays demonstrated that the MAPK inhibitor did not alter the 
protective effect of T3 in the presence of any drugs, while the incubation with the PI-3K- 
inhibitor abolished the protective effect of T3 on the cells exposed to H2O2 and SNAP, 
which indicates this effect as PI-3 kinase-dependent. Furthermore, we investigated 
whether the inhibition of PKA by using Rp-cAMP (50 µM) was able to interfere with the 
protective effect of the hormone; as shown by MTT assay, the presence of Rp-cAMP did 
not affect the cell survival induced by the hormone treatment in any case. 
A major downstream target of the activated PI-3K is the serine-threonine kinase Akt, and 
the activation of the enzyme by phosphorylation on Thr308 (by PI-3K) and by 
autophosphorylation on Ser473 has been associated with the inhibition of apoptosis 
(Dickson and Rhodes, 2004). To determine whether T3-regulated cell survival was 
associated with the activation of Akt, Western Blot analysis with an antibody specific for 
the phosphorylated Thr308 Akt was performed, too. As shown in the Figure 7, panel d, a 
specific band for pAkt was detected only in the cells treated with drugs (H2O2 and SNAP) 
and concurrently with T3 10-7M in both the cell lines, while it was absent in the cells treated 
with drugs alone, according to MTT results. It is interesting to mention that the 
phosphorylation of Akt on the Thr residue, as shown in the Figure 7, panel d, was 
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upregulated also by the hormone treatment alone, in accordance with the very recent 
observation that T3 is able to regulate Akt phosphorylation via PI-3 K (Cao et al, 2005). 
These data suggest that the T3 treatment is able to promote cell survival via the specific 
activation of PI-3 K and the phosphorylation of the protein kinase B on Thr 308.
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Figure 7 T3 protects RINm5F and CM cells from apoptosis induced by H2O2 and SNAP via PI-
3 K activation and Akt phosphorylation
RINm5F (black) and CM (white) cells were cultured in the presence or the absence of T3 10-
7M, in the presence of LY-294002 hydrochloride (50 µM), PD098059 (50 µM) or Rp-cAMP (50 
µM), as indicated on x axis, and concurrently exposed to H2O2 (50 µM, 30min) (a), SNAP (200 
µM 24h) (b) and streptozocin (15mM 24h) (c). Cell viabilities were measured by MTT assay 
and presented as % of the control OD value (y axis). All the data are presented as means ± SD 
and are the results of five different experiments at least. A comparison of the individual 
treatment was conducted by using one-way ANOVA followed by Tukey post-hoc test. * = P< 
0.05; ** = P < 0.01. A  P value <0.05  was considered significant.
d. RINm5F (at the edge) and CM (at the bottom) cells were cultured in the presence or the 
absence of T3 10-7M and concurrently exposed to H2O2, SNAP and streptozocin. Western 
Blot analyses were performed as described in Materials and Methods and a specific band 
corresponding to the phosphorylated Akt (Thr 308) (77kDa) was detected. The expression of β-
actin (44 kDa) was analyzed as a control for gel loading. At least three different experiments 
were performed, and a representative one is showed here.
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T3 induces rapid activation of  Akt in a CHX-insensitive manner 
As we previously demonstrated  (Verga Falzacappa et al. 2006), the ability of T3 to 
counteract apoptosis in hcm and rRINm5F cells is mediated by PI3K and involves an Akt 
activation by T3 after 24h of hormone treatment.  To examine the mechanisms underlying 
this new survival effect of the thyroid hormone T3,  we decided to examine firstly the earlier 
time course of Akt activation by T3 treatment. hCM and rRINm5F cells were cultured in the 
presence or the absence of the hormone treatment (T3 10-7M) for 10 and 30 min., and 
then were T3 deprived for the same times. In addition cells, in the presence of T3 10-7, 
were incubated with the thyroid hormone receptor antagonists Bisphenol A and TRIAC (10 
µM). The 10µM concentration of  each inhibitor was chosen as the more efficacious after 
preliminary experiments performed with three different concentrations (100 nm, 1µm AND 
10 µm) (data not shown). As discussed above BPA can disrupt the action of T3 through 
the thyroid hormone receptor (Moriyama et al. 2002), differently TRIAC is a thyroid 
hormone analogue which is specifically able to potentiate T3 effect on transcription 
through TRβ isoforms (Messier and Langlois, 2000).  A negative control for Akt 
phosphorylation was obtained by incubating the cells with the PI3K inhibitor LY294,002 
hydrochloride 10 µM. As shown in figure 8 Ser 473 phosphorylation of Akt was detected as 
early as 10 min after T3 addition and persisted up to 30 min in both hCM and rRINm5F 
cells. This effect appeared to be T3 dependent, since the deprivation of the hormone from 
cell culture media led to a decrease in the phosphorylation level of Akt after 30 min up to 
the basal level;  moreover the effect resulted T3 dependent as suggested by the ability of 
BPA to block the phosphorylation, and seemed to be independent by gene transcription 
since the presence of TRIAC could not augment pAkt expression. In particular Western 
Blot analyses revealed that the activation of Akt by T3 was affected by BPA in a dose-
dependent manner, so that we chose the 1µM concentration for the other experiments. 
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The T3 action we observed did not require de novo protein synthesis;  the addiction of the 
protein synthesis inhibitor CHX to the culture medium indeed did not affect the Ser 473 
phosphorylation of Akt even after 30 min of exposure to T3. These data support our 
hypothesis that the T3 activation of Akt is mediated by a non-genomic mechanism.
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Figure8  T3 induces rapid activation of  pAkt in a CHX-insensitive manner
Cells were exposed to T3 (10-7M),  and then deprived of the hormone treatment for the 
indicated times. Cells treated with T3 (30 min) were also exposed  to LY (10µM), BPA (100 
nM, 1µM and 10µM) or TRIAC (100 nM, 1µM and 10µM) (upper panel), or to BPA 10 µM, 
TRIAC 10 µM (middle and lower panels). Additionally samples were hormone treated and 
concurrently exposed to cycloheximide 3 mM for 30’ (lower panel). Western Blot analyses 
were performed as described in Materials and Methods and a specific band corresponding to 
the phosphorylated Akt (Thr 308 or Ser 473) was detected. The expression of 
unphosphorylated Akt  was analyzed as a control for gel loading. Densitometric absorbance 
values from three separate experiments were averaged (± SD), after they had been 
normalized to Akt for equal loading. Data are presented in the hystogram as percentages (y 
axis), using control as baseline (100%). The different experimental groups are indicated on the 
x axis. A comparison of the individual treatment was conducted by using Student’s t test. * = 
P< 0.05; ** = P < 0.01. A  P value <0.05  was considered significant. At least three different 
experiments were performed, and a representative one is shown here.
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TRβ1 exists in the cytoplasmic region and is able to colocalize with PI3Kp85α 
As we observed, the effect of T3 on Akt phosphorylation was rapid and CHX independent.   
Nongenomic actions of thyroid hormones have recently begun to be elucidated, in 
particular different hypotheses on the linkage between binding sites and hormone actions 
have been made. Our results evidenced that BPA but not TRIAC can influence the T3 
effect on the activation of Akt, moreover the activation was not influenced by CHX, thus 
suggesting a nongenomic mechanism for this T3 action, presumably taking place out of 
the nucleus. The Akt phosphorylation is specifically due to PI3K, which resides at the 
plasma membrane; since a cytoplasmic location for thyroid receptor has been shown 
(Davis PJ et al. 2000; Zhu XG, 1998), we decided to investigate whether a thyroid receptor 
was detectable in a subcellular localization of the examined cells. As shown in figure 3, 
panels a and d, both hCM and rRINm5F cells immunostained for TRβ1 showed a positivity 
at the cytoplasmic level, showing the presence of the thyroid receptor in this cell 
compartment of hCM and rRINm5F cells. Once the cells have been counterstained for the 
p85α subunit of PI3K images by fluorescence microscopy were merged to evaluate the 
localization of both the protein analyzed. Interestingly, the TRβ1 and the PI3Kp85α were 
able to colocalize at a cytoplasmic level. This ability and the expression level of each 
single protein was not affected by the hormone treatment (data not shown), indicating this 
to be a ligand independent effect. The cytosol localization of TRβ1 was moreover 
confirmed by the detection of a specific band in the Western Blot analyses, panels b (hCM) 
and e (RINm5F), performed on the cytosolic fractions of the cells. As shown, TRβ1 was 
clearly detectable at the nuclear level in both immunofluorescence and Western Blot 
analyses, confirming its typical localization is not altered in the analyzed cells. 
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TRβ1 complexes with PI3Kp85α but not with PI3Kp110 in a ligand-independent manner 
Thyroid receptors have recently been demonstrated to act nongenomically similarly to 
other steroid receptors, in particular  Cao et al. (2005) and Storey et al. (2006) have shown 
an interaction between the subunit p85α of PI3K and the thyroid receptor β1, similar to that 
observed for the estrogen receptor α (Simoncini et al. 2000). Given the results obtained by 
the immunofluorescence experiments, we decided to analyze the ability of TRβ1 and PI3K-
p85α to form a complex. As shown in figure 9, panels c and f, immunoprecipitation with 
anti- TRβ1 antibody resulted in pulling down of the catalytic subunit of PI3K p85α in the 
presence or the absence of the hormone T3 and of its analogues BPA and TRIAC. In the 
same experimental condition the presence of the regulatory subunit of PI3K p110 was not 
detectable (data not shown), indicating that only the p85α subunit can be pulled down by 
TRβ1 .These data indicate that TRβ1 and PI3Kp85α can form a complex in a ligand-
independent manner. Together with the evidences obtained by fluorescence microscopy 
and cytosol Western Blot, these data suggest this complex to be located at the cytosol or 
at the plasmamembrane level.
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Figure 9 TRβ1 is present at a cytoplasmic level and complexes with PI3Kp85α
Immunofluorescence analysis (hCM panel a; rRINm5F panel d). Cells were cultured and 
immunostained for TRβ1 (green fluorescence), and subsequently for PI3Kp85α (red 
fluorescence); nuclei were counterstained with Hoechst. The images were then merged to 
evidence the colocalization of the two signals. The images were acquired and analysed 
through fluorescence mycroscopy as described in Materials and Methods. Western Blot 
analyses performed specifically on the cytosol and nuclear fractions of hCM (b) and rRINm5F 
(e) cell extracts were analysed for the presence of TRβ1, as described in Materials and 
Methods. Coimmunoprecipitation experiments (hCM panel c; rRINm5F panel f). Cells were 
exposed to T3 and then deprived of the hormone treatment for the indicated times, and the 
same cells were also exposed to BPA (10µM), or TRIAC (10µM); immunoprecipitation
experiments for TRβ1  were performed on total extracts. Western Blot analyses for PI3Kp85α
and TRβ1 were performed as described in Materials and Methods. All the data shown are 
representative of at least three independent experiments.
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T3 induces TRβ1 associated PI3K activity 
To investigate whether T3 was able to affect the PI3K activity, a  competitive ELISA assay 
was performed on TRB1 pulled down samples. Samples were collected from cells (hCM 
and RINm5F) exposed or not to the hormone treatment for 30 mins and exposure to LY 10 
µM was used as a negative control. Since the two cell lines showed a similar trend, we 
decided to show only the results obtained for the human cell line hCM. As shown in figure 
10, panel a, the presence of T3 provoked an increase in the kinase activity of about 2 
folds; the PI3K activity, infact, was about 90 pmol/mg protein/hour in the control samples of 
hCM cells, while it reached 200 pmol/mg protein/hour in the hormone treated samples. 
These data indicate that, although the hormone treatment does not influence the formation 
of the complex between p85α and TRβ1, it is able to induce the kinase activity in the TRβ1 
associated PI3K. 
 
T3 induces Akt activity 
To evaluate if the increase in Akt phosphorylation levels was accompanied by an increase 
in the Akt kinase activity, activation of specific Akt substrates was analyzed by Western 
Blot analyses. One of the main target of Akt activity are the Glucogen Sinthetase Kinases 
α/β, which are specifically phosphorylated on the Ser 9 and Ser 21 residues by Akt (Cross 
et al, 1995); as shown in figure 10, panel b, Western Blot analyses performed on the same 
samples utilized for Akt activation evaluation, were performed for the analysis of GSK 3 α 
phosphorylation levels. Interestingly the phosphorylation of GSK3 α  was increased by the 
hormone treatment already after 10 mins and returned to basal level when the hormone 
treatment was deprived from the cell culture media. Moreover the addition of neither BPA 
nor TRIAC was able to affect the T3 effect on this phosphorylation. These data suggest 
that the thyroid hormone T3 is able to fully activate Akt, thus promoting its kinase activity, 
in both hCM and rRINm5F cells.
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Figure 10  T3 induces TRB1 associated PI3K activity and Akt activity
PI3K activity: hCM and rRINm5f cells were exposed to T3 (10-7M) alone or concurrently to T3 and 
LY (10 µM) and to vehicle alone for 30 min. Then total extracts were immunoprecipitated for 
TRB1 and analyzed for PI3K activity as described in Materials and Methods. The kinase activity 
was estimated by comparing the values from the samples to those in the standard curve.  All the 
data are presented as means ± SD and are the results of five different experiments at least in 
which every sample was run in triplicate. 
Akt activity: hCM and RINm5F cells were cultured in the presence or not of T3 (10-7M) and 
inhibitors for the indicated times. Western Blot analyses were performed as described in Materials 
and Methods and a specific band corresponding to the phosphorylated GSK3α (Ser 9) was 
detected. The expression of GSK3α was analyzed as a control for gel loading. Densitometric
absorbance values from three separate experiments were averaged (± SD), after they had been 
normalized to GSK3α for equal loading. Data are presented in the hystogram as fold of induction 
(y axis), calculated as treated sample/control. The different experimental groups are indicated on 
the x axis. A comparison of the individual treatment was conducted by using Student’s t test. * = 
P< 0.05; ** = P < 0.01. A  P value <0.05  was considered significant. At least three different 
experiments were performed, and a representative one is shown here. 
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T3 induces the  nuclear translocation of activated Akt  
To better understand the dinamics of the activation observed, the cells exposed to the 
hormone treatment (T3) were immunostained for pAkt-Ser 473 and analyzed with a 
fluorescence microscope equipped for confocal microscopy. After stimulation through 
PI3K, Akt is recruited to the plasma membrane where it is activated by phosphorylation. 
Once activated, pAkt is translocated to the different  cell compartments, including the 
nucleus, where its target proteins are.  
We have analyzed the T3 effect on the localization of pAkt (Ser 473) in hCM and rRINm5F 
cells as shown in figure 11, panels a (hCM) and c (rRINm5F). As shown, activated pAkt-
Ser 473 was rapidly translocated to the nucleus, leading to a stronger fluorescence in this 
cell compartment. Interestingly, this effect was promptly increased by the presence of the 
hormone treatment (30 min), suggesting that T3 can firstly promote the activation of Akt 
and later its subsequent nuclear relocalization.  To confirm the observed phenomena, 
Western Blot analyses were performed on the separate cytosol and nuclear fractions of 
the cells exposed to the hormone treatment for 10 and 30 min. As shown in panels b 
(hCM) and d (RINm5F), the phosphorilated Akt levels were remarkably augmented in the 
nuclear fraction of treated cells, suggesting that the increase observed in pAkt levels in the 
whole proteins is mainly due to the nuclear fraction.  The quality and the loading of the 
extracts were normalized by histone H1 (nucleus) and α-tubulin (cytosol) blotting as 
shown. These data suggest that in our cellular systems T3 is able to increase Akt 
activation by specific phosphorylation on Ser 473 and promotes its nuclear localization as 
resulted in the cells exposed to the hormone. 
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Figure 11 T3 induces nuclear translocation of pAkt
hCM (panel a) and rRINm5F (panel c) cells were exposed to T3 (10-7M) or vehicle alone for 30 
min and then immunostained for pAktS as described in Materials and Methods, and images were 
analyzed by confocal microscopy. Additionally Western Blot analyses on the cytoplasmic and 
nuclear fractions of proteins extracts from hCM (b) and rRINm5F cells (d) exposed to T3 
treatment for 30 min. and a specific band corresponding to the phosphorylated Akt (Ser 473) 
was detected. The expression of histone H1 (nuclear) and α-tubulin (cytosolic) were analyzed as 
a control for gel loading and to exclude the contamination of the cytosol with the nuclear 
components and viceversa.  At least three different experiments were performed, and a 
representative one is shown here.
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The T3 activation of Akt in β cells depends on TRβ1 
To confirm the crucial role of  the thyroid receptor β1 for the T3 activation of Akt via PI3K 
pathway in hCM and rRINm5F cells, we analyzed if the specific silencing of TRβ1 could 
alter the T3 ability to promote Akt phosphorylation. TRβ1 was “knocked down” in rRINm5F 
and hCM  by  siRNA experiments. hCM and RINm5F cells were transfected with TRβ1 
siRNAs and exposed or not to T3 treatment; total extracts were then immunoblotted for 
TRβ1 and pAkt. As shown in figure 12, panels a and b, when TRβ1 was silenced, as 
demonstrated by Western Blot analyses, the phosphorylation of Akt induced by T3 was 
completely abolished, on the other hand the TRβ1 silencing per se was not able to 
influence the abasal activation of Akt in the β cells analyzed. These data strongly indicated 
that the ability of T3 to induce Akt activation in the islet cells utilized, is specifically 
mediated by the thyroid receptor β1. 
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Figure 12 TRβ1 interference abolishes T3 effect on Akt activation
RNA interference experiments to silence TRβ1 expression were performed as described in 
Materials and Methods on hCM (a) and rRINm5F (b) cells exposed or not to T3 (10-7M) for the 
indicated times. Western Blot analyses were performed as described in Materials and Methods 
and a specific band corresponding to the phosphorylated Akt (Ser 473) and TRβ1was detected. 
The expression of Akt  was analyzed as a control for gel loading. t least three different 
experiments were performed, and a representative one is shown here.
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Discussion 
In this study we demonstrated a novel T3 action which specifically target pancreatic β 
cells. At first we analyzed the physiological aspect of this action, secondly we investigate 
the molecular mechanisms underlting the T3 survival action. 
T3 as a survival factor for pancreatic β cells 
Throughout the lifetime of a mammal, low levels of β-cell replication and apoptosis are 
balanced and result in a slowly increasing mass (Bonner Weir, 2000). The physiological 
control of the β-cell mass in normal and pathological conditions is based on the balance of 
proliferation, differentiation, and death of the insulin secreting cells. Apoptosis plays an 
essential role in diabetic pathology, but, as it is involved in the β-cell death usually 
occurring in islet transplantation, it is also critical for the diabetes treatment (Butler et al, 
2003). Factors that can augment the β-cell mass are of particular interest in the field of the 
diabetes treatment, and to date many growth factors have been already investigated as 
potential agents to increase or preserve the islet β-cell mass  (Nielsen et al, 2001). 
In this study we used the rat RINm5F cell line (Bargsten, 2004; Sjohol, 1995), commonly 
used to study both physiological and pathophysiolological mechanisms of the β-cell 
damage. Furthermore, in order to investigate our hypothesis in man, too, we decided to 
use the CM cell line. Human insulinoma cell lines are rarely used because of the difficulties 
existing in obtaining and culturing them for long periods (Adcock et al, 1975). CM cells 
represent one of the very few human long-term culture β-cell lines (Baroni et al, 1999; 
Cavallo et al, 1996). Although the behaviour of none of the most widely used insulin-
secreting cell lines perfectly mimics primary β-cell physiology, they are extremely valuable 
tools for the study of molecular events underlying β-cell function and dysfunction (Poitout 
et al, 1996).  
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Thyroid Hormones and Cell Cycle 
In agreement with other studies showing a high expression of TRs in the endocrine 
pancreas (Zinke et al, 2003; Shahrara et al, 1999), we have shown that thyroid receptors 
are highly expressed in both the selected cell lines, in agreement with the evidences in the  
pancreatic tissue by Lee et al, 1990. 
 The thyroid hormone has been suggested to be a paradoxical hormone inducing 
either growth stimulatory or inhibitory effects, depending on the tissue involved and the 
treatment regimen (Yen, 2001). We were able to demonstrate that the hormone treatment 
(T3 10-7M) led to an induction of up to 55% -rRINm5F- and 45% -hCM- in cell number after 
72 hours of treatment and that such induction was accompanied by a shortening of the 
doubling time of the cell lines we have analyzed, moreover the utilization of the T3 
analogue BPA suggested this induction to be due specifically to the thyroid hormone 
receptors involvement.  
T3 has been reported to be able to regulate the expression of several genes playing a key 
role in cell-cycle control via stimulation of the G1-cyclins (Barrera-Hernandez et al, 1999; 
Pibiri et al, 2001). We have shown that the expression of cyclins A, D1 and E was 
stimulated by T3 suggesting that one of the mechanisms by which these proteins were 
increased was due to the action of T3 at transcriptional and/or post-transcriptional level. In 
this study, the indication given by BPA experiments and the increase induced by the T3 
treatment in the TR levels could suggest a relation between TRs and proliferative effect of 
T3; however, we cannot rule out that the modulation of the cycle-related molecules may 
depend on both a direct and an indirect effect of T3. So, further studies should be 
addressed to this topic.  
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β-cell Apoptosis 
We have investigated the effects of T3 on islet β-cells undergoing apoptosis; some 
cell-cycle regulators can actually influence both cell division and programmed cell death 
(Vermeulen et al, 2003; King  and Cidlowski, 1998). In this study we utilized H2O2, SNAP 
and streptozocin, which have widely been utilized in β-cell apoptosis studies, to induce 
apoptosis in the RINm5F and CM cells.The selected drugs were able to induce apoptosis, 
and the administration of T3 to the islet cells, before (H2O2, streptozocin) or during (SNAP) 
the exposure to the drugs, had a significant protective effect against cell apoptosis. To 
investigate which factors could be implied in such a protective role of T3, we examined the 
expression of some of the main regulators of cell apoptosis, that is, the prosurvival Bcl-2 
and Bcl-XL, and the proapoptotic Bax and Bad. Recent studies (Thomas et al, 2002) 
demonstrated that isolated human islets express Bax at higher level than Bcl-2, and 
suggest the balance between pro-survival and pro-apoptotic molecules to be one of the 
main mechanisms underlying islet cell death by apoptosis. Thus, it could be possible that a 
reduced expression of Bax might help preserving the β-cell mass. Our data show that T3 
causes an increase in the expression of prosurvival factors in cells treated with drugs, and 
that this effect is accompanied by a decrease in proapoptotic proteins, suggesting that this 
might be one of the mechanism involved in the survival activity of the hormone. Moreover, 
we analyzed the effect of T3 on the cleavage of proCaspase 3 and we demonstrated that 
the expression of the active caspase 3 was decreased by the hormone treatment when the 
cells had been exposed either to streptozocin or to H2O2. We also observed a 
downregulation of the cleaved p85 PARP in the same conditions (data not shown). 
All the analyzed proteins were regulated even by the hormonal treatment alone 
independently from the activation of an apoptotic cascade, suggesting that T3 acts via a 
regulation of cellular endogenous factors and in accordance with the observation that the 
 66
Discussion 
T3 was not able to counteract apoptosis, when it was added immediately after the 
exposure to H2O2 and streptozocin. 
 
T3 As a Survival Factor 
PI-3 K and MAPK are two well-known signalling molecules mediating cell 
proliferation, differentiation and apoptosis. The PI-3 K inhibitor LY294002 was able to 
abolish the antiapoptotic action of the thyroid hormone ─ which suggests the involvement 
of a partial regulation via a PI-3 K-dependent mechanism. The activated PI-3 K can inhibit 
programmed cell death, presumably via Akt (Franke et al, 2003). We evidenced that the 
phosphorylation of Akt (Thr308), that is specifically due to PI-3 K, occurred only in those 
cells exposed to H2O2 and SNAP concurrently to the thyroid hormone. Such 
phosphorylation is also enhanced by T3 alone; this demonstrates that T3 is able to activate 
the PI-3 K pathway. Our data are in accordance with the very recent findings by Cao et al 
(2005), that ascertain a novel role for the thyroid hormone T3 in activating the PI-3 K 
pathway in a non-genomic manner. In fact, the authors define the ability of T3 to activate 
PI-3 K via the cytoplasmic action of TRβ1, and to regulate directly the phosphorylation of 
Akt.  
It has been demonstrated (Webster and Anwer, 1998) that the involvement of cAMP in the 
cytoprotection against bile acid-induced apoptosis includes PI-3 K, PKA and MAPK. 
However, it has also been shown that ─ in the protection from apoptosis ─ signalling 
through PI-3 K and Akt/PKB may occur independently from cAMP (Ikeuchi et al, 1998). To 
analyze the role of cAMP in the protective effect of T3 in our systems in vitro, we used the 
PKA inhibitor Rp-cAMP and demonstrated that this inhibitor did not alter the protective 
effect of thyroid hormone, which suggests that T3 is capable of activating a specific 
survival pathway in islet β-cells undergoing apoptosis. This pathway involves PI-3 K in a 
cAMP-independent manner.  
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The MAPK pathways transduce a variety of external signals leading to cell growth, 
differentiation and apoptosis. Since the use of PD098059 did not affect the ability of T3 to 
inhibit apoptosis, we suggest that this pathway is not involved either in the protective 
action of the thyroid hormone or in the phosphorylation of Akt. However, we did not 
investigate the other MAPK pathways, thus we do not rule out that these may be involved 
in the antiapoptotic effect of the hormone, therefore, to this aim, further studies should be 
conducted . 
In conclusion, in the first part of our study we demonstrated that not only the thyroid 
hormone T3 should be considered a proliferative factor for islet β-cells in vitro, but it also is 
able to promote survival when an apoptotic cascade is activated. We have shown that this 
protective effect is due to a regulation of different cellular apoptotic proteins and that the 
thyroid hormone (T3) is specifically able to activate the PI-3 K pathway, so regulating the 
phosphorylation of Akt. These observations may have important clinical and therapeutic 
implications for the current strategies designed for the diabetes treatment, such as islet 
transplantation and β-cell protection. 
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TRβ 1 and the PI3K pathway 
The thyroid hormone T3 is usually known to access to the cell interior and to the cell 
nucleus, where it binds to its nuclear receptors and transactivates thyroid-hormone 
regulated genes. This action, classically referred to as genomic, happens in hours to days, 
which is consistent with the typical hormone action, including regulation of cell growth, 
development and metabolism. On the other hand, a different mechanism has been 
observed, which induces very fast responses in cells, happening within minutes or even 
seconds, and it is called nongenomic or extranuclear action. Such effects have actually 
been known since many years, but their mechanisms still remain unclear. Since the 10% 
of TRs are cytoplasmic in the absence of T3 (Baumann  et al. 2001), one of the main 
question to be answered is what kind of factors mediate this thyroid hormone action. 
In particular it is not yet  been clarified whether  a new thyroid hormone receptor is 
involved in the nongenomic action, although no specific membrane associated TR isoform 
has been identified yet,  or if  the well known one has novel additional functions.    
In this study we evidenced in pancreatic β cells that the PI3K pathway can be considered a 
target of the nongenomic T3 action and that the thyroid receptor β1 is essential in 
mediating this T3 action. 
 
Akt and β cell function 
The factors that drive β cell proliferation and function under normal or pathological 
condition are still unknown. Available data indicate that there exists a plethora of β cell 
growth factors acting in genetically heterogeneous and presumably oligogenic fashion 
(Nielsen et al. 1999). Cellular processes such as proliferation, survival and glucose 
metabolism induced by different hormones and growth factors are dependent on the 
activation of PI3-kinase; moreover the involvement of Akt in the regulation of replication 
and survival of pancreatic β cells has largely been demonstrated (Lingor et al. 2003;  Tuttle 
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et al. 2001). Multiple Akt substrates are involved in regulating various aspects of β cell 
function, in this view augmented protein synthesis represents an important component of 
the growth response, but not the sole effector. Nevertheless the activation of protein 
kinase B can occurr within minutes and be related to nongenomic action of specific 
activators of the PI3K pathway.  
 
Akt activation 
The thyroid hormones have recently been demonstrated to induce Akt activation (Cao et 
al. 2005;  Kuzman et al. 2005), and this effect happening in minutes or hours. In this study 
we demonstrated that T3 (10-7M), whose role in β cell growth and survival we previously 
evidenced (Verga Falzacappa et al. 2006), provokes Akt phosphorylation in minutes, this 
effect being independent on de novo protein synthesis. 
Activation of Akt entails a complex series of events involving additional proteins. First the 
PI3-K generated lipid products PI(3,4,5)P3 and PI(3,4)P2 recruit Akt to the plasma 
membrane through their affinity for the PH domain of Akt (Burgering et al. 1995; Franke et 
al. 1997). Once membrane proximal, at least two residues of Akt are rapidly 
phosphorylated (Thr 308 and Ser 473) by PI3K activity. Active Akt can rapidly translocate 
to specific intracellular compartments. This ordered series of events is necessary to 
generate fully activated Akt and has been demonstrated even in in vivo models (Scheid et 
al. 2002), moreover a strict control on the location and activation of Akt probably reflects 
the direct consequences of chronically activated Akt in disease. In this study we 
demonstrated how the T3 treatment is able to influence these events, in particular inducing 
the translocation of active Akt to the nucleus. 
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TRβ1 and PI3K: T3 nongenomic action 
Optimal signaling through the PI3K pathway depends on a critical molecular balance 
between the regulatory and catalitic subunits; in particular the p85α subunit is thought to 
be the major response pathway for most stimuli (Shepherd et al. 1998). The relation 
between Akt activation and T3 action remains to be elucidated, Cao et al. (2005) and 
Storey et al. (2006) have demonstrated that the thyroid receptor β1 is able to interact with 
the regulatory subunit p85α of the PI3K. This ability of a nuclear receptor of complexing 
with the regulatory subunit of PI3K was already observed for the estrogen receptor ERα 
(Simoncini et al. 2000), for which controversy exists concerning whether or not it has a role 
outside the nucleus (Pietras et al. 1977). It has been suggested that such non-genomic 
actions might be mediated by membrane associated isoforms of the classical nuclear 
receptors with significantly different agonist/antagonist affinities (Losel 2003). We 
demonstrated  that the β1 isoform of thyroid receptor, not only is able to form a complex 
with the p85α subunit, but also is clearly detectable in the cytoplasmic area of the cells 
examined.  Interestingly  we show  that although the interaction between PI3K and a TRβ1 
is not influenced by the presence of the hormone, T3 treatment can enhance the TRβ1 
associated PI3K activity. In fact it has been demonstrated that thyroid receptors can locate 
outside the nucleus in the absence of T3 (Baumann et al, 2001), thus expalining that the 
TRβ1-PI3K binding does not require the T3 presence. Otherwise, the presence of the 
hormone does stimulate the kinase activity, when it is complexed to TRβ1. These data 
suggest that the hormone is somehow able to activate the kinase and that this action is 
TR-mediated. In addition we demonstrated that this T3 action can trigger a cascade of 
events PI3K dependent; in fact not only Akt is activated by T3, but also its activity is 
influenced by the presence of the hormone. Our findings evidenced that phosphorylation of 
GSK3-α, one of the main Akt targets, is enhanced by the hormone treatment and that even 
this activation shows a trend similar to those observed for Akt phosphorylation itself. These 
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data suggest that the full activation of Akt  induced by T3 via PI3K activity stimulation, 
leads to an increment even in Akt kinase activity.Moreover, given the evidences of the 
cytoplasmic localization of TRβ1 our data support the hypothesis that nuclear thyroid 
receptors might exist also outside the nucleus (Davis PJ et al. 2000; Zhu et al. 1998) 
playing an important role in non-genomic actions of  thyroid hormone. 
We also evidenced that the “knock down” of the gene encoding TRβ1, through 
experiments of RNA interference, led to an abolishment of the Akt activation induced by 
T3, and once again the role of TRβ1 seems to be essential.  
 
IRS2 role 
Phosphoinoisitide 3-kinase plays a pivotal role in the metabolic and mitogenic actions of 
insulin, following insulin stimulation the IRS proteins bind to class 1a PI3K, thereby 
increasing its activity (Shepherd et al. 1998, Bonni et al. 1999). In pancreatic β cells the 
direct binding between IRS-2 and PI3K leads to Akt activation,  modulating the cell 
survival, the proliferation and the cell size (Accili et al. 2001). Moreover, other studies on 
the knock out mice for IRS-2 evidenced an augmented β cell apoptosis, indicating IRS-2 
as crucial in regulating β cell mass and survival (Dickson  and Rhodes, 2004). We also 
analyzed IRS-2 expression after a long-term (24h) treatment with T3; the protein 
expression of IRS-2 resulted upregulated by the hormone treatment (data not shown) 
suggesting that T3 interact with the PI3K pathway even at this level.  The effect observed 
could be due to the classical genomic T3 action acting synergistically with nongenomic 
mechanisms. If all the effects of IRS-2 are mediated by Akt, there must be additional 
players, which are likely to include effectors of the apoptotic cascade, transcriptional 
factors and additional kinases. In this context we could speculate that TRβ1 plays a 
specific role directly entering the PI3K pathway.  
 72
Discussion 
Our data showed that the thyroid receptor β1 complexes with the p85α subunit of PI3K 
and it is well known that even the binding between IRS-2 and PI3K involves the same 
subunit through the SH2 domain of p85α (Cantley LC. 2002) and the phosphorylated (Tyr) 
IRS. TR has been shown to be a phosphoprotein, although a tyrosine phosphorylation has 
not yet been reported (Jones et al. 1994; Davis et al. 2000). Thus it is unlikely that the 
binding between TRβ1 and p85α we reported involves the SH2 domain. On the other 
hand, it has been shown that p85α binds some proteins through its Rho-GAP domain, 
which includes three repeats of LXXLL motifs (Swiss prot accession no. Q63787).  This 
sequence is considered a good candidate to interact with nuclear receptors and it has 
been identified in various nuclear receptor associating proteins. Given these observations 
we can speculate that the interaction between TRβ1 and PI3K might take place at the level 
of the Rho-GAP domain of p85α, without compromising the ability of PI3K to interact with 
IRS-2. Our data, according to the observation of Cao et al. (2005) support the hypothesis  
that the interaction between TRβ1 and PI3K takes place in the cytosol or near the plasma 
membrane. In conclusion we suggest that a “cytoplasmic” thyroid receptor exists in the 
pancreatic β cells RINm5F and CM, this receptor should be similar to  the nuclear TRβ1 
form, but with some peculiar characteristics that led  its location.  
 
T3 nongenomic action 
Baumann et al. (2001) have shown that TRβ rapidly shuttles between the nucleus and the 
cytoplasm. The possible modes of interaction between non genomic  and genomic thyroid 
hormone signalling are complex but they appear to act synergistically. The postulated non 
genomic signalling pathway may complement such actions by generating second 
messengers and by activating multiple signalling cascades. For example the genomic and 
non genomic effects of thyroid hormones, in the mitochondria, also appear to be strikingly 
synergistic. (Bassett et al. 2003). These findings reveal the complexity of the TR signaling 
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and suggest that a thyroid receptor with high omology to the nuclear one at least, if not the 
same itself, might be the centre of the effects we characterized in pancreatic beta cells. 
Short interfering RNAs, designed to specifically act on nuclear TRβ1 mRNA, can silence 
both cytoplasmic and nuclear TRβ1 without distinction (data not shown); in addition  the 
commercial monoclonal antibody against the nuclear thyroid hormone receptor recognizes 
something that is responsible for  the T3 effect observed and that is located in the 
cytoplasm, strenghtening our hypothesis that a thyroid hormone receptor with high 
similarities to the nuclear one but with a peculiar localization is involved. However given 
the complexity of  the TR shuttling mechanisms and since the precise events underlying 
this phenomenon are not still known , additional studies are needed to clarify the roles of 
TRβ1 in these non genomic effects of thyroid hormones.   
In conclusion we suggest that a “cytoplasmic” thyroid receptor exists in the pancreatic β 
cells RINm5F and CM that is able to mediate the T3 action on the PI3K signaling pathway; 
this receptor should be similar to  the nuclear TRβ1 form, but with some peculiar 
characteristics that led  its location. 
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